<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10525888</article-id><article-id pub-id-type="doi">10.3390/antibiotics12091462</article-id><article-id pub-id-type="publisher-id">antibiotics-12-01462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antimicrobial Peptides (AMP) in the Cell-Free Culture Media of <italic toggle="yes">Xenorhabdus budapestensis</italic> and <italic toggle="yes">X. szentirmaii</italic> Exert Anti-Protist Activity against Eukaryotic Vertebrate Pathogens including <italic toggle="yes">Histomonas&#x000a0;meleagridis</italic> and <italic toggle="yes">Leishmania donovani</italic> Species</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3495-0154</contrib-id><name><surname>Fodor</surname><given-names>Andr&#x000e1;s</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-antibiotics-12-01462" ref-type="aff">1</xref><xref rid="c1-antibiotics-12-01462" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3535-5157</contrib-id><name><surname>Hess</surname><given-names>Claudia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-antibiotics-12-01462" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ganas</surname><given-names>Petra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-antibiotics-12-01462" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Boros</surname><given-names>Zs&#x000f3;fia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-antibiotics-12-01462" ref-type="aff">1</xref><xref rid="af3-antibiotics-12-01462" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0506-5474</contrib-id><name><surname>Kiss</surname><given-names>J&#x000e1;nos</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af3-antibiotics-12-01462" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Makrai</surname><given-names>L&#x000e1;szl&#x000f3;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af4-antibiotics-12-01462" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6913-219X</contrib-id><name><surname>Dublecz</surname><given-names>K&#x000e1;roly</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af5-antibiotics-12-01462" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9838-6703</contrib-id><name><surname>P&#x000e1;l</surname><given-names>L&#x000e1;szl&#x000f3;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af5-antibiotics-12-01462" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2711-0229</contrib-id><name><surname>Fodor</surname><given-names>L&#x000e1;szl&#x000f3;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af6-antibiotics-12-01462" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Sebesty&#x000e9;n</surname><given-names>Anna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af7-antibiotics-12-01462" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Michael G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af8-antibiotics-12-01462" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6310-186X</contrib-id><name><surname>Tarasco</surname><given-names>Eustachio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af9-antibiotics-12-01462" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Kulkarni</surname><given-names>Manjusha M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af10-antibiotics-12-01462" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>McGwire</surname><given-names>Bradford S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af10-antibiotics-12-01462" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Vellai</surname><given-names>Tibor</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-antibiotics-12-01462" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6991-0120</contrib-id><name><surname>Hess</surname><given-names>Michael</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-antibiotics-12-01462" ref-type="aff">2</xref><xref rid="c1-antibiotics-12-01462" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>De Biasi</surname><given-names>Margherita-Gabriella</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Dini</surname><given-names>Irene</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-12-01462"><label>1</label>Department of Genetics, Institute of Biology, E&#x000f6;tv&#x000f6;s Lor&#x000e1;nd University, P&#x000e1;zm&#x000e1;ny P&#x000e9;ter. s&#x000e9;t&#x000e1;ny 1C, H-1117 Budapest, Hungary; <email>boroszsofia@student.elte.hu</email> (Z.B.); <email>vellai.tibor@ttk.elte.hu</email> (T.V.)</aff><aff id="af2-antibiotics-12-01462"><label>2</label>Clinic for Poultry and Fish Medicine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine (Vetmeduni Vienna), 1210 Vienna, Austria; <email>claudia.hess@vetmeduni.ac.at</email> (C.H.); <email>petra.ganas@bfr.bund.de</email> (P.G.)</aff><aff id="af3-antibiotics-12-01462"><label>3</label>Agribiotechnology and Precision Breeding for Food Security National Laboratory, Department of Microbiology and Applied Biotechnology, Institute of Genetics and Biotechnology, Hungarian University of Agriculture and Life Sciences, P&#x000e1;ter K&#x000e1;roly utca 1, H-2100 G&#x000f6;d&#x000f6;ll&#x00151;, Hungary; <email>kiss.janos@uni-mate.hu</email></aff><aff id="af4-antibiotics-12-01462"><label>4</label>Autovakcina Kft., H-1171 Budapest, Hungary; <email>makrai.laszlo@univet.hu</email></aff><aff id="af5-antibiotics-12-01462"><label>5</label>Institute of Physiology and Nutrition, Georgikon Campus, Hungarian University of Agriculture and Life Sciences (MATE), De&#x000e1;k Ferenc utca 16, H-8360 Keszthely, Hungary; <email>dublecz.karoly@uni-mate.hu</email> (K.D.); <email>pal.laszlo@uni-mate.hu</email> (L.P.)</aff><aff id="af6-antibiotics-12-01462"><label>6</label>Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, H-1143 Budapest, Hungary; <email>fodor.laszlo@univet.hu</email></aff><aff id="af7-antibiotics-12-01462"><label>7</label>First Department of Pathology and Experimental Cancer Research, Semmelweis University, H-1085 Budapest, Hungary; <email>sebestyen.anna@semmelweis.hu</email></aff><aff id="af8-antibiotics-12-01462"><label>8</label>USDA-ARS &#x00026; Department of Entomology, The Ohio State University, 13416 Claremont Ave, Cleveland, OH 44130, USA; <email>klein.10@osu.edu</email></aff><aff id="af9-antibiotics-12-01462"><label>9</label>Department of Soil, Plant and Food Sciences, University of Bari &#x0201c;Aldo Moro&#x0201d;, Via Amendola 165/A, 70126 Bari, Italy; <email>eustachio.tarasco@uniba.it</email></aff><aff id="af10-antibiotics-12-01462"><label>10</label>Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; <email>manjumkulkarni@gmail.com</email> (M.M.K.); <email>brad.mcgwire@osumc.edu</email> (B.S.M.)</aff><author-notes><corresp id="c1-antibiotics-12-01462"><label>*</label>Correspondence: <email>fodor.andras@ttk.elte.hu</email> or <email>fodorandras@yahoo.com</email> (A.F.); <email>michael.hess@vetmeduni.ac.at</email> (M.H.)</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2023</year></pub-date><volume>12</volume><issue>9</issue><elocation-id>1462</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>01</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Anti-microbial peptides provide a powerful toolkit for combating multidrug resistance. Combating eukaryotic pathogens is complicated because the intracellular drug targets in the eukaryotic pathogen are frequently homologs of cellular structures of vital importance in the host organism. The entomopathogenic bacteria (EPB), symbionts of entomopathogenic&#x02013;nematode species, release a series of non-ribosomal templated anti-microbial peptides. Some may be potential drug candidates. The ability of an entomopathogenic&#x02013;nematode/entomopathogenic bacterium symbiotic complex to survive in a given polyxenic milieu is a coevolutionary product. This explains that those gene complexes that are responsible for the biosynthesis of different non-ribosomal templated anti-microbial protective peptides (including those that are potently capable of inactivating the protist mammalian pathogen <italic toggle="yes">Leishmania donovanii</italic> and the gallinaceous bird pathogen <italic toggle="yes">Histomonas meleagridis</italic>) are co-regulated. Our approach is based on comparative anti-microbial bioassays of the culture media of the wild-type and regulatory mutant strains. We concluded that <italic toggle="yes">Xenorhabdus budapestensis</italic> and <italic toggle="yes">X. szentirmaii</italic> are excellent sources of non-ribosomal templated anti-microbial peptides that are efficient antagonists of the mentioned pathogens. Data on selective cytotoxicity of different cell-free culture media encourage us to forecast that the recently discovered &#x0201c;easy-PACId&#x0201d; research strategy is suitable for constructing entomopathogenic-bacterium (EPB) strains producing and releasing single, harmless, non-ribosomal templated anti-microbial peptides with considerable drug, (probiotic)-candidate potential. </p></abstract><kwd-group><kwd>non-ribosomal anti-microbial peptides (NR-AMP)</kwd><kwd>entomopathogenic nematode-symbiont bacteria (EPB)</kwd><kwd><italic toggle="yes">Xenorhabdus</italic></kwd><kwd><italic toggle="yes">X. budapestensis</italic></kwd><kwd><italic toggle="yes">X. szentirmaii</italic></kwd><kwd><italic toggle="yes">X. innexii</italic></kwd><kwd><italic toggle="yes">Photorhabdus</italic> (<italic toggle="yes">P. luminescens TT01</italic>)</kwd><kwd>CFCM (cell-free conditioned culture media)</kwd><kwd>kinetoplastid protozoa parasite</kwd><kwd><italic toggle="yes">Leishmania</italic></kwd><kwd>extracellular avian pathogens</kwd><kwd><italic toggle="yes">Histomonas meleagridis</italic></kwd><kwd>probiotic potential</kwd></kwd-group><funding-group><award-group><funding-source>Hungaria Research Fund</funding-source><award-id>K132439</award-id><award-id>K 128203</award-id></award-group><award-group><funding-source>NKFIH</funding-source><award-id>RRF-2.3.1-21-2022-00007</award-id></award-group><award-group><funding-source>State of Hungary</funding-source><award-id>T&#x000c1;MOP-4.2.2/B-10/1-2010-0025</award-id></award-group><award-group><funding-source>EU</funding-source></award-group><award-group><funding-source>Hess&#x02013;Dublecz project</funding-source></award-group><award-group><funding-source>Bradford McGwire in Columbus, OH, USA</funding-source></award-group><funding-statement>These project has partly been funded by Prof. Vellai, OTKA (Hungaria Research Fund) Grant Number: K132439 at the Department of Genetics, E&#x000f6;v&#x000f6;s University Another source of funding: Dr. J&#x000e1;nos Kiss, OTKA (Hungarian Research Fund) Grant Number: K 128203. The experiments in G&#x000f6;d&#x000f6;ll&#x00151; (J.K., Zs.B.) were also supported by RRF-2.3.1-21-2022-00007 from NKFIH (Nemzeti Kutat&#x000e1;si, Fejleszt&#x000e9;si &#x000e9;s Innov&#x000e1;ci&#x000f3;s Hivatal, <uri xlink:href="https://nkfih.go">https://nkfih.go</uri>, Hungary). The &#x0201c;EMA-EMC International Project&#x0201d; started at the Department of Genetics, E&#x000f6;tv&#x000f6;s University; several other labs have been involved but have also been terminating here, although a significant part has been accomplished somewhere else. The Histomonas experiment was part of the Hungarian&#x02013;Austrian international cooperation and supported by the T&#x000c1;MOP-4.2.2/B-10/1-2010-0025 project based on the financial support of the State of Hungary and the EU. The CFCM preparations for Histomonas experiments were supported by the Hess&#x02013;Dublecz project (recently a joint unit of the Hungarian University of Agriculture and Life Sciences (MATE). The Leishmania experiments were supported by the bench money of Bradford McGwire in Columbus, OH, USA.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-12-01462"><title>1. Introduction</title><p>Anti-microbial peptides (AMPs) are any polyamide, or even their bio-co-polymer with esters, thioesters, or otherwise modified backbone, that can be made on a contemporary chemical peptide synthesizer [<xref rid="B1-antibiotics-12-01462" ref-type="bibr">1</xref>]. This provides an option of taking advantage of using the remarkable toolkit of quantitative structure&#x02013;activity relation (QSAR) [<xref rid="B2-antibiotics-12-01462" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-12-01462" ref-type="bibr">3</xref>] in designing novel anti-microbial-active sister molecules of any newly discovered natural drug-candidate AMP molecule. As for their biosynthesis, peptides of anti-microbial potential can be either ribosomal encoded (RP) single gene products [<xref rid="B4-antibiotics-12-01462" ref-type="bibr">4</xref>] or enzymatically biosynthesized non-ribosomal templated peptides (NRP) [<xref rid="B5-antibiotics-12-01462" ref-type="bibr">5</xref>], (NR-AMPs) [<xref rid="B6-antibiotics-12-01462" ref-type="bibr">6</xref>]. Considering that there are already &#x0003e;100 peptide-based drugs that have been of clinical use (see [<xref rid="B7-antibiotics-12-01462" ref-type="bibr">7</xref>]), an lookout at that field may be advisable. As for history, we refer to the review of Zasloff [<xref rid="B8-antibiotics-12-01462" ref-type="bibr">8</xref>], who outlined those discoveries that can be considered as milestones, like cecropins [<xref rid="B9-antibiotics-12-01462" ref-type="bibr">9</xref>], defensins [<xref rid="B10-antibiotics-12-01462" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-12-01462" ref-type="bibr">11</xref>], maganins [<xref rid="B12-antibiotics-12-01462" ref-type="bibr">12</xref>], and add the proline-rich AMP (PrAMP family) [<xref rid="B13-antibiotics-12-01462" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-12-01462" ref-type="bibr">14</xref>] to the still incomplete list. Many derivatives of discovered natural AMPs have been chemically synthesized and or modified, and there are several excellent reviews [<xref rid="B15-antibiotics-12-01462" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-12-01462" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-12-01462" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-12-01462" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-12-01462" ref-type="bibr">19</xref>] beyond the scope of this paper.</p><p>The two selected targets here are <italic toggle="yes">Leishmania</italic> [<xref rid="B20-antibiotics-12-01462" ref-type="bibr">20</xref>], a mammalian pathogen, transmittable by insects like cave-dwelling sand flies [<xref rid="B21-antibiotics-12-01462" ref-type="bibr">21</xref>], and <italic toggle="yes">Histomonas meleagridis</italic>, the etiological agent of the life-threatening histomonosis (syn. blackhead disease) of poultry species such as turkeys, chickens, and pheasants, first described in 1893 [<xref rid="B22-antibiotics-12-01462" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-12-01462" ref-type="bibr">23</xref>], and have been studied in detail until the mid of last century [<xref rid="B24-antibiotics-12-01462" ref-type="bibr">24</xref>]. </p><p>In the actual study we aimed to investigate if any of those biosynthetic NR-AMPs, like fabclavine [<xref rid="B25-antibiotics-12-01462" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-12-01462" ref-type="bibr">26</xref>], phenazine [<xref rid="B27-antibiotics-12-01462" ref-type="bibr">27</xref>], and others, produced by entomopathogenic&#x02013;nematode symbiont bacteria (EPB) we have been studying [<xref rid="B28-antibiotics-12-01462" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-12-01462" ref-type="bibr">29</xref>] were suitable as anti-protozoal drug candidates against the intracellular parasite <italic toggle="yes">Leishmania</italic> or the extracellular parasite <italic toggle="yes">H. meleagridis</italic>. The arguments for choosing in vitro EPB liquid cultures as appropriate sources of efficient AMPs for this purpose are that obligate bacterial symbionts of entomopathogenic&#x02013;nematode species synthesize and release several non-ribosomal hybrid peptides [<xref rid="B30-antibiotics-12-01462" ref-type="bibr">30</xref>] with large target specificities. These mainly serve to provide well-balanced pathobiome conditions for this symbiosis in polyxenic soil and cadaver environments [<xref rid="B31-antibiotics-12-01462" ref-type="bibr">31</xref>]. These peptides are also considered potential sources of potent natural anti-microbial compounds [<xref rid="B30-antibiotics-12-01462" ref-type="bibr">30</xref>]. The motivation for choosing in vitro EPB liquid cultures as a source of efficient AMPs for this purpose is the proven activity on Gram-positive [<xref rid="B32-antibiotics-12-01462" ref-type="bibr">32</xref>,<xref rid="B33-antibiotics-12-01462" ref-type="bibr">33</xref>] and Gram-negative [<xref rid="B34-antibiotics-12-01462" ref-type="bibr">34</xref>] pathogenic bacteria, oomycetes, and different plant pathogens [<xref rid="B35-antibiotics-12-01462" ref-type="bibr">35</xref>,<xref rid="B36-antibiotics-12-01462" ref-type="bibr">36</xref>] in our previous studies. Since we have reasons to believe that some of the autoclaved <italic toggle="yes">Xenorhabdus</italic> cultures may not be harmful or toxic when added as a food supplement, while some anti-microbial ingredients retain active [<xref rid="B6-antibiotics-12-01462" ref-type="bibr">6</xref>], we consider the potential for probiotic applications, at least on an experimental level. </p><p>The eukaryotic pathogens studied here include the <italic toggle="yes">Leishmania donovanii</italic> species, kinetoplastid protozoa [<xref rid="B37-antibiotics-12-01462" ref-type="bibr">37</xref>], and the causative agent of human and canine leishmaniasis [<xref rid="B38-antibiotics-12-01462" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-12-01462" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-12-01462" ref-type="bibr">40</xref>].</p><p><italic toggle="yes">Leishmania</italic> are intracellular parasites that target professional phagocytes (macrophages and dendritic cells) [<xref rid="B41-antibiotics-12-01462" ref-type="bibr">41</xref>] and human infection leads to diverse forms of disease from singular or diffuse cutaneous lesions (cutaneous leishmaniasis), invasive destruction of mucous membranes (mucocutaneous leishmaniasis), or dissemination to the liver, spleen, and bone marrow (visceral leishmaniasis) [<xref rid="B42-antibiotics-12-01462" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-12-01462" ref-type="bibr">43</xref>]. While mainly relegated to endemic foci in poor rural areas in the third world, the infections have a global impact due to human migration, climate change, and anthropogenic disturbance, causing significant worldwide health and economic burdens [<xref rid="B44-antibiotics-12-01462" ref-type="bibr">44</xref>]. There are currently no approved vaccines available [<xref rid="B45-antibiotics-12-01462" ref-type="bibr">45</xref>], leaving control of leishmaniasis reliant on chemotherapy [<xref rid="B46-antibiotics-12-01462" ref-type="bibr">46</xref>]. The mainstays of therapy are antimonial derivatives [<xref rid="B47-antibiotics-12-01462" ref-type="bibr">47</xref>] of amphotericin B (AmB), a polyene macrolide antibiotic derived from actinomycetes [<xref rid="B48-antibiotics-12-01462" ref-type="bibr">48</xref>], which can be renally toxic and are not widely available in poor rural areas. Increasingly, there are issues with leishmanial infections that are resistant or refractory to antimony and amphotericin therapy. Miltefosine is the first oral agent approved for the treatment of leishmaniasis; however, there have been descriptions of miltefosine resistance [<xref rid="B46-antibiotics-12-01462" ref-type="bibr">46</xref>]. There is an obvious need for the development of newer, less toxic agents to combat these infections.</p><p>The other chosen pathogen, <italic toggle="yes">H. meleagridis</italic>, belongs to the Dientamoebidae, order <italic toggle="yes">Tritrichomanidida</italic>. Infections in turkeys may cause nearly 100% mortality whereas outbreaks in chickens, peafowl, quail, and pheasants are more often marked by morbidity and subsequent recovery. <italic toggle="yes">H. meleagridgridis</italic> is carried by the eggs of the cecal worm <italic toggle="yes">Heterakis gallinarum</italic>, enabling them to survive for long periods in the soil as a source of infection [<xref rid="B22-antibiotics-12-01462" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-12-01462" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-12-01462" ref-type="bibr">24</xref>]. In the EU and USA, there are currently no drugs available for the treatment of blackhead disease [<xref rid="B22-antibiotics-12-01462" ref-type="bibr">22</xref>,<xref rid="B24-antibiotics-12-01462" ref-type="bibr">24</xref>]. (As for molecular taxonomy and identification, the 5.8S, ITS-1, and ITS-2 rRNA regions were first sequenced [<xref rid="B49-antibiotics-12-01462" ref-type="bibr">49</xref>]. Since then, the complete, annotated <italic toggle="yes">Histomonas</italic> reference genome sequence became available [<xref rid="B50-antibiotics-12-01462" ref-type="bibr">50</xref>]).</p><p>Since the introduction of effective drugs into the market in the middle of the previous century, there was no practical need for further research. Following the recent ban of available drugs, research programs with new profiles were set up in various places focusing on different features of the parasite and the disease. </p><p>Consequently, the poultry industry works without approved prophylactics, therapeutics, or vaccines to combat histomonosis [<xref rid="B51-antibiotics-12-01462" ref-type="bibr">51</xref>].</p><p>Recently, numerous chemical and botanical compounds were also tested for their efficacy against <italic toggle="yes">H. meleagridis</italic>, with varying outcomes. One of the explanations for these half-failures/half-successes may be the complicated in vitro <italic toggle="yes">Histomonas</italic> culturing technique. In this context, it is of high importance that <italic toggle="yes">H. meleagridis</italic> relies on live bacteria and <italic toggle="yes">Escherichia coli</italic> strongly supports the growth of <italic toggle="yes">H. meleagridis</italic> in a monoxenic culture without influencing its pathogenicity [<xref rid="B52-antibiotics-12-01462" ref-type="bibr">52</xref>]. In the previously mentioned study, a clonal cultures of <italic toggle="yes">H. meleagridis</italic> was further optimized to obtain a monoxenic culture in a liquid medium [<xref rid="B52-antibiotics-12-01462" ref-type="bibr">52</xref>]. For this, the fecal flora was exchanged for defined bacterial strains by selective destruction of the initial bacteria with various antibiotics, keeping the flagellate alive. <italic toggle="yes">E. coli</italic> was found to strongly support the growth of the parasite, whereas <italic toggle="yes">Salmonella enterica</italic> serovar Typhimurium and <italic toggle="yes">Pseudomonas aeruginosa</italic> were less efficient. Whether the special feature of the parasite&#x02019;s intricate interplay with bacteria in vitro and in vivo can be considered mutualistic or a predator-prey one is an open question [<xref rid="B50-antibiotics-12-01462" ref-type="bibr">50</xref>,<xref rid="B51-antibiotics-12-01462" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-12-01462" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-12-01462" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-12-01462" ref-type="bibr">54</xref>,<xref rid="B55-antibiotics-12-01462" ref-type="bibr">55</xref>,<xref rid="B56-antibiotics-12-01462" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-12-01462" ref-type="bibr">57</xref>,<xref rid="B58-antibiotics-12-01462" ref-type="bibr">58</xref>,<xref rid="B59-antibiotics-12-01462" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-12-01462" ref-type="bibr">60</xref>]. (We are shared about it). The option of the monoxenic culturing technique may open a door to preliminary attempts to protect birds with cultured attenuated histomonads, forecasting the possibility of vaccination [<xref rid="B56-antibiotics-12-01462" ref-type="bibr">56</xref>].</p><p>After banning all previously used prophylactic and therapeutic drugs against <italic toggle="yes">H. meleagridis</italic> in the USA and the European Union, benzimidazoles were tested but found inactive [<xref rid="B61-antibiotics-12-01462" ref-type="bibr">61</xref>]. Similar half-successes were reported about various herbal substances, some of which showed good efficacy in vitro but failed in vivo [<xref rid="B62-antibiotics-12-01462" ref-type="bibr">62</xref>]. Reduced sensitivity of <italic toggle="yes">H. meleagridis</italic> to nitarsone in vitro and in vivo was also shown [<xref rid="B63-antibiotics-12-01462" ref-type="bibr">63</xref>]. </p><p>A publication talked about that, identical monoxenic settings for cultures of the same <italic toggle="yes">H. meleagridis</italic> clonal strain, in its virulent low-passage and attenuated high-passage form, enabled a comparative analysis of parasite characteristics [<xref rid="B64-antibiotics-12-01462" ref-type="bibr">64</xref>], but the conclusions severely contradict a previously cited, unambiguously reliable publication [<xref rid="B59-antibiotics-12-01462" ref-type="bibr">59</xref>]. This debate is out of scope of the present paper.</p><p>Herein, we compared the spectrum of in vitro anti-microbial/-prozozoal activity of cell-free conditioned culture media (CFCM) from three EPB species, together with testing against <italic toggle="yes">Leishmania donovanii</italic>, (together with <italic toggle="yes">Trypanosoma cruzi</italic>, as an expectedly negative control), <italic toggle="yes">Histomonas meleagridis</italic>, and also against a panel of clinical bacterial and fungal isolates, as positive controls. Considering the roles of the bacterial symbiont in the EPN/EPB symbiosis, we suppose that ani-protozoal compounds must coexist with other anti-microbial compounds in the CFCM of EPBs. Therefore, for reliable bioassays, we should use appropriate controls. Two main aspects should be taken into consideration: (A) To be able to distinguish between the specified antiprotist activity and general cytotoxicity of the future drug-candidate anti-microbial compounds in the CFCM. (B) To be able to identify the special antiprotist compounds. In this paper, we describe the very first steps toward these goals. For (A), one has to consider that the lack of uniformity regarding the choice of cell types for cytotoxicity assays may lead to incomparable and inconclusive data. In vitro assays relying solely on non-phagocytic cell models may not represent a realistic result, as the effect of an anti-leishmanial agent should ideally be presented based on its cytotoxicity profile against reticuloendothelial system cells [<xref rid="B65-antibiotics-12-01462" ref-type="bibr">65</xref>]. In the <italic toggle="yes">Leishmania</italic> studies, we used the macrophage cell line J774A.1 [<xref rid="B66-antibiotics-12-01462" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-12-01462" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-12-01462" ref-type="bibr">68</xref>], as a cytopathogenicity control test organism (see <xref rid="sec2-antibiotics-12-01462" ref-type="sec">Section 2</xref> Materials and Methods). In the <italic toggle="yes">Histomonas</italic> studies, we used the permanent chicken liver cells (LMH leghorn male hepatoma) cell line [<xref rid="B6-antibiotics-12-01462" ref-type="bibr">6</xref>,<xref rid="B69-antibiotics-12-01462" ref-type="bibr">69</xref>,<xref rid="B70-antibiotics-12-01462" ref-type="bibr">70</xref>] as a cytopathogenicity control test organism (see <xref rid="sec2-antibiotics-12-01462" ref-type="sec">Section 2</xref> Materials and Methods). For (B), one has to take into consideration the following points: each NR-AMP-producing EPB cell is in the so-called primary (1<sup>0</sup>) phase, or Phase 1 [<xref rid="B71-antibiotics-12-01462" ref-type="bibr">71</xref>]. In other terms, the phenotypic precondition for antibiotic production (as well as the capability of symbiosis) of the EPB species is the primary phase [<xref rid="B30-antibiotics-12-01462" ref-type="bibr">30</xref>,<xref rid="B72-antibiotics-12-01462" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-12-01462" ref-type="bibr">73</xref>]. For NR-AMP production, it means that in a liquid culture of the primary (1<sup>0</sup>) cells (of each of the studied EPB species, strain, and isolate), more than one biosynthetic AMP is present simultaneously. Each expresses anti-microbial (maybe antiprotist) activity, so the anti-microbial (antiprotist) activity of a CFCM sample represents a cumulative activity. However, in an optimal test system, one would prefer to determine the anti-microbial activity of each of the single anti-microbial compounds one by one. </p><p>Since the discovery that the activity (the &#x0201c;switch-on&#x0201d;/&#x0201c;switch-off&#x0201d; states) of those group genes (operons, biosynthetic gene complexes, and BGCs), which are responsible for the primary-secondary phenotypic phase shift in each known EPB strain, not only work under the control of the versatile regulator hexA [<xref rid="B74-antibiotics-12-01462" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-12-01462" ref-type="bibr">75</xref>], but are also coordinately regulated at a higher level (via <italic toggle="yes">hfq</italic>-gene controlled sRNS/HexA-mRNA base pairing). More precisely, the Hfq-dependent sRNA, ArcZ, directly base-pairs with the HexA-encoding mRNA [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-12-01462" ref-type="bibr">78</xref>]; it is possible to construct double-mutant strains from each EPB species (or isolate) following the genuine strategy called easyPACId (easy promoter-activated compound identification) approach [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>]. Each biosynthesizes and releases only one single NR-AMP molecule into the culture media. This discovery may be a starting point of the renaissance of <italic toggle="yes">Xenorhabdus</italic> anti-microbial peptide research [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-12-01462" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-12-01462" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-12-01462" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-12-01462" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-12-01462" ref-type="bibr">83</xref>]. We managed to reconstruct the &#x0201c;easyPACId&#x0201d; <italic toggle="yes">hfq</italic> deletion mutant strains from EMA and EMC (Boros et al., in preparation) and publish here some information, including data about their anti-microbial potential. In this paper, we give an account of the details of constructing our <italic toggle="yes">hfq</italic>-del mutants from our EMA and EMC [<xref rid="B29-antibiotics-12-01462" ref-type="bibr">29</xref>] strains and provide their phenotypic descriptions. Our &#x0201c;easyPACId&#x0201d; strains will be available for cooperation with fellow scientists worldwide. </p></sec><sec id="sec2-antibiotics-12-01462"><title>2. Materials and Methods</title><p>The plasmids [<xref rid="B84-antibiotics-12-01462" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-12-01462" ref-type="bibr">85</xref>,<xref rid="B86-antibiotics-12-01462" ref-type="bibr">86</xref>,<xref rid="B87-antibiotics-12-01462" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-12-01462" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-12-01462" ref-type="bibr">89</xref>,<xref rid="B90-antibiotics-12-01462" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-12-01462" ref-type="bibr">91</xref>,<xref rid="B92-antibiotics-12-01462" ref-type="bibr">92</xref>] used in this study [<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>] are listed in <xref rid="antibiotics-12-01462-t0A1" ref-type="table">Table A1</xref> in <xref rid="app2-antibiotics-12-01462" ref-type="app">Appendix A</xref>. Several different entomopathogenic bacteria (EPB) species were used as producers of anti-microbial compounds. Various clinical isolates of Gram-positive and Gram-negative bacteria served as test organisms, as did eukaryotic organisms (protozoa, fungi, and murine macrophages). Plasmids with a temperature-sensitive pSC101 replication system were produced in <italic toggle="yes">E. coli</italic> at 30 &#x000b0;C under antibiotic selection [<xref rid="B84-antibiotics-12-01462" ref-type="bibr">84</xref>]. For cloning purposes, <italic toggle="yes">E. coli</italic> TG1 [<xref rid="B85-antibiotics-12-01462" ref-type="bibr">85</xref>] was used as the host strain. For plasmid mobilization into <italic toggle="yes">Xenorhabdus</italic>, <italic toggle="yes">E. coli</italic> S17-1&#x003bb; pir [<xref rid="B86-antibiotics-12-01462" ref-type="bibr">86</xref>] was applied. <italic toggle="yes">E. coli</italic> strains were routinely grown in conventional Luria&#x02013;Broth (LB) liquid media at 37 &#x000b0;C in the presence of the appropriate selective antibiotics. </p><sec id="sec2dot1-antibiotics-12-01462"><title>2.1. NR-AMP-Producing EPB Strains, Test Organisms, and Bioassays of CFCMs </title><sec id="sec2dot1dot1-antibiotics-12-01462"><title>2.1.1. The Anti-Microbial Activity of EPB CFCMs Was Assessed against Trypanosomatid Protozoa </title><p><italic toggle="yes">Leishmania donovanii</italic>, and <italic toggle="yes">T. cruzi</italic>, using both the native (i.e., centrifuged and sterile-filtered) and heat-sterilized (i.e., centrifuged, sterile-filtered, and autoclaved) CFCMs of liquid cultures of three species of anti-microbial-producing EPB strains, EMA, EMC, and EMK (<italic toggle="yes">Xenorhabdus budapestensis</italic> nov. DSM16342(T)) [<xref rid="B28-antibiotics-12-01462" ref-type="bibr">28</xref>], <italic toggle="yes">X. szentirmaii</italic> nov. DSM16338(T)) [<xref rid="B28-antibiotics-12-01462" ref-type="bibr">28</xref>], and <italic toggle="yes">X. innexii</italic> nov. DSM16337(T) [<xref rid="B8-antibiotics-12-01462" ref-type="bibr">8</xref>,<xref rid="B28-antibiotics-12-01462" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-12-01462" ref-type="bibr">29</xref>] were bioassayed with promastigotes and epimastigotes of <italic toggle="yes">Leishmania amazonensis</italic> and <italic toggle="yes">T. cruzi</italic> (Brazil strain), respectively, as well as on clinical isolates of Gram-positive bacteria (methicillin-sensitive and -resistant <italic toggle="yes">Staphylococcus aureus</italic>) and Gram-negative bacteria (<italic toggle="yes">Francisella novicida</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Salmonella typhimurium</italic>, and <italic toggle="yes">P. aeruginosa</italic>), and with the yeast, <italic toggle="yes">Candida albicans</italic>. The J774 murine macrophage cells served as a control for measuring the general eukaryotic cytopathogenicity of the CFCMs [<xref rid="B68-antibiotics-12-01462" ref-type="bibr">68</xref>] (see below and <xref rid="antibiotics-12-01462-t001" ref-type="table">Table 1</xref> for additional details). </p></sec><sec id="sec2dot1dot2-antibiotics-12-01462"><title>2.1.2. The Anti-Protozoan Activity of EPB CFCMs </title><p>EPB CFCMS were assessed against the protists. <italic toggle="yes">H. meleagridis</italic> of both the native and heat-sterilized (as previously described) CFCMs from liquid cultures of two anti-microbial-producing EPB strains (Pl.-Yellow and Pl.-RED). They were both grown in Medium 199 containing Earle&#x02019;s salts, L-glutamine, 25 mM HEPES, L-amino acids, 15% heat-inactivated fetal bovine serum (FBS) and 0.22% rice starch for 65 h at 30 &#x000b0;C, representing the type color colony variants (yellow and red) of the EPB species <italic toggle="yes">P. luminescens</italic> TT01 [<xref rid="B93-antibiotics-12-01462" ref-type="bibr">93</xref>] distinguishable on MacConkey [<xref rid="B94-antibiotics-12-01462" ref-type="bibr">94</xref>] agar plates.</p></sec></sec><sec id="sec2dot2-antibiotics-12-01462"><title>2.2. Bioassays</title><sec id="sec2dot2dot1-antibiotics-12-01462"><title>2.2.1. Bioassays on <italic toggle="yes">Leishmania</italic>, <italic toggle="yes">T. cruzi</italic>, and Control Test Organisms</title><p>The bioassays were extended to clinical pathogenic protozoa using previously described routine methods [<xref rid="B95-antibiotics-12-01462" ref-type="bibr">95</xref>]). The CFCM of EMA and EMC (stored at 4 &#x000b0;C for two years) were used for these experiments. Both native and autoclaved CFCM were tested in each bioassay. Samples of EMA-CFCM and EMC-CFCM were also fractionated using Centricon spin columns, as described by the manufacturer (Millipore, Sigma, Burlington, MA, USA), and fractions from &#x0003c;3 kDa and &#x0003e;3 kDa were assayed for activity. The bioassays were carried out in 96-hole tissue culture plates, in 200 &#x000b5;L volumes, containing 95 &#x000b5;L of the respective liquid media, 100 &#x000b5;L cell-free respective CFCM, and 5 &#x000b5;L of overnight LB cultures of the respective test organisms in duplicate. Briefly, colony count assays were used to measure activity against clinical isolates of bacteria and Candida. Overnight incubation in 25&#x02013;100 microliters of a LB medium was followed by plating on a solid medium. MTT utilization assays were performed after overnight incubation of cultures of stationary phase pro- or epimastigotes, respectively, with CFCM (1:1 ratio) for 4 h for anti-leishmanial and -trypanosomal activity. Untreated controls were assayed in parallel with the LB medium alone. A reduction of CFUs (for bacteria or Candida) or MTT activity (for protozoa) of at least 80% was considered + for anti-microbial activity. Cytopathogenecity for mammalian cells was assessed using the macrophage cell line J774A.1 (TIB-67; ATCC, Manassas, VA, USA) in MTT assays and light microscopy. J774 cells [<xref rid="B66-antibiotics-12-01462" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-12-01462" ref-type="bibr">67</xref>] were grown in DMEM with high glucose (25 mM) and 1.5 g/L NaHCO3, 50,000 U/L penicillin 50 mg/L streptomycin, and 10% FCS (heat-inactivated). Cells were grown in bioreactor tubes in an incubator at 37 &#x000b0;C and 5% CO<sub>2</sub>. The J774 cells were passaged twice a week, similar to those described [<xref rid="B68-antibiotics-12-01462" ref-type="bibr">68</xref>]. As for positive and negative controls, the CFCMs used in these experiments were only those that showed any kind of anti-microbial activity either against Gram-positive (<italic toggle="yes">B. subtilis</italic>) or Gram-negative (<italic toggle="yes">E. coli</italic> OP50) or <italic toggle="yes">Candida</italic> targets in previous experiments. The anti-microbial activities of each CFCM used in these experiments in Columbus (Ohio) had been determined in Wooster (Ohio, Klein Laboratory) right after they were obtained. Then, three years later, just before being used in <italic toggle="yes">Leishmania</italic> experiments in Columbus, that is, after a three-year store. No significant difference was detectable. In Columbus, each replicate was accompanied by the respective negative and positive control flasks, containing (i) only media, (ii) media + test organism without CFCM, and (iii) media plus CFCM only and without test organisms. The test organisms were naturally <italic toggle="yes">Leishmania</italic>, <italic toggle="yes">T. cruzii</italic>, <italic toggle="yes">Candida</italic>, MRSA, MSSA, <italic toggle="yes">Pseudomonas</italic>, <italic toggle="yes">E. coli</italic>, and J77, respectively.</p></sec><sec id="sec2dot2dot2-antibiotics-12-01462"><title>2.2.2. Bioassays on <italic toggle="yes">H. meleagridis</italic> Grown in Monoxenic Culture with <italic toggle="yes">E. coli</italic></title><p>Each of the CFCMs mentioned above was tested on <italic toggle="yes">Histomonas</italic> grown in an in vitro monoxenic culture with <italic toggle="yes">E. coli</italic> DH5&#x003b1; cells. The monoxenic culture of <italic toggle="yes">H. meleagridis</italic> Turkey/Austria/2922-C6/04 with <italic toggle="yes">E. coli</italic> DH5&#x003b1; was grown in Medium 199 containing Earle&#x02019;s salts, L-glutamine, 25 mM HEPES, L-amino acids, 15% heat-inactivated fetal bovine serum FBS, and 0.22% rice starch for 72 h at 40 &#x000b0;C, as described [<xref rid="B52-antibiotics-12-01462" ref-type="bibr">52</xref>,<xref rid="B59-antibiotics-12-01462" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-12-01462" ref-type="bibr">60</xref>]. Consequently, the anti-<italic toggle="yes">E.coli</italic> activities also had to be determined. In the first experiment (see <xref rid="app1-antibiotics-12-01462" ref-type="app">Supplementary Material</xref>), the anti-histomonal tests were cell-free filtrates from cultures of <italic toggle="yes">P. luminescens</italic> TT01 yellow and red variants, prepared as described above and tested on <italic toggle="yes">E.coli</italic> that were then plated, On the resective table (Table 2 in the <xref rid="sec3-antibiotics-12-01462" ref-type="sec">Section 3</xref> Results) we can see qualitative data (&#x0201c;sigle colonies&#x0201d;, &#x0201c;cell layers&#x0201d;).</p><p>As described in detail in the <xref rid="app1-antibiotics-12-01462" ref-type="app">Supplementary Material</xref>, the liquid medium of the protozoan culture was removed and replaced either by different CFCMs (in different concentrations) (Experimental groups), or fresh media (Control groups). The <italic toggle="yes">Histomonas</italic> cell numbers were determined. This experimental was set up for trying to distinguish between the reasons for the death of the CFCM-treated <italic toggle="yes">Histomonas</italic> cells: whether they died by direct anti-protozoal effects of the EPB-released (&#x0201c;CFCM-born&#x0201d;) AMPs, or by the indirect consequences of the death of their mutualistic prokaryote partner <italic toggle="yes">E. coli</italic> DH5@ cells.</p><p>The unchanged protozoan cultures and protozoan cultures in which the culture medium was replaced by fresh Medium 199 supplemented with 15% FBS were used as controls. Each of the different CFCM analyses was performed in triplicate. The cultures were incubated at 40 &#x000b0;C and evaluated every 24 h by counting the protozoan cells. </p></sec></sec><sec id="sec2dot3-antibiotics-12-01462"><title>2.3. Construction and Bioassay of the Anti-Microbial Potential of hfq(del) Mutants of EMA and EMC</title><sec id="sec2dot3dot1-antibiotics-12-01462"><title>2.3.1. Construction of <italic toggle="yes">hfq</italic>(del) Mutants of EMA and EMC (for Details, see <xref rid="app2-antibiotics-12-01462" ref-type="app">Appendix A</xref>)</title><p>The &#x00394;hfq mutant EMC strain was generated according to the one-step gene inactivation method [<xref rid="B87-antibiotics-12-01462" ref-type="bibr">87</xref>], which was adapted to <italic toggle="yes">Photorhabdus</italic> [<xref rid="B88-antibiotics-12-01462" ref-type="bibr">88</xref>] and <italic toggle="yes">Xenorhabdus.</italic> The protocol was as follows: The appropriately modified plasmids (<xref rid="antibiotics-12-01462-t0A1" ref-type="table">Table A1</xref> in <xref rid="app2-antibiotics-12-01462" ref-type="app">Appendix A</xref>, for plasmids) were introduced into <italic toggle="yes">X. szentirmaii</italic> (EMC) by electroporation. Electrocompetent cells were prepared for the introduction of plasmids as follows: 1 mL of <italic toggle="yes">X. szentirmaii</italic> (EMC) culture grown at 30 &#x000b0;C in a LB broth supplemented with ampicillin (Ap) (150 &#x003bc;g/mL) to OD600~1.1&#x02013;1.2, centrifuged for 30 s at 9000 rpm at 2 &#x000b0;C. Then, resuspended in an ice-cold wash SMG buffer (0.5 M sorbitol, 0.5 M mannitol, 10% glycerol) and centrifuged again. The washing step was repeated two times; then, the cells were resuspended in a 60 &#x003bc;L SMG buffer. Approximately 1 &#x003bc;g of plasmid DNA purified by the Qiagen Plasmid Midi Kit according to the manufacturer&#x02019;s protocol was added to 40 &#x003bc;L of electrocompetent cells. Electroporation was carried out using 2 mm gap electroporation cuvettes and a BTX Electro Cell Manipulator 600 with the setting 129 Ohm, 24 kV/cm. Transformants were selected on LB plates supplemented with the appropriate antibiotics (kanamycin (Km)&#x02014;120 &#x003bc;g/mL, streptomycin (Sm)&#x02014;100 &#x003bc;g/mL, gentamicin (Gm)&#x02014;50 &#x003bc;g/mL, and Ap&#x02014;150 &#x003bc;g/mL). For the <italic toggle="yes">hfq</italic> KO recombination, EMC cells containing plasmid pBZs7 were grown in a LB broth supplemented with the appropriate antibiotics to a late logarithmic (OD<sub>600</sub>~1.1&#x02013;1.2) phase; then, the culture was 2&#x000d7; diluted with a fresh LB broth. L-arabinose was added in a final concentration of 1% and grown further in a shaker for 1.5 h at 30 &#x000b0;C. The electro-competent cells were prepared as described above. The KO PCR fragment was amplified using a pKD4 template plasmid and the primers hfq EMCdelfor and hfq EMCdelrev. The amplicon was precipitated in 96% ethanol, dried, and resuspended in 10 mM Tris pH 8.0. For electroporation, approximately 1 &#x003bc;g of a purified DNA fragment was used as described. After electroporation, cells were grown for 5 h at 30 &#x000b0;C, then spread on LB agar plates supplemented with 120 &#x003bc;g/mL Km and incubated at 30 &#x000b0;C for 2 days. The &#x00394;hfq::Km<sup>R</sup> recombinant was tested by colony PCRs. For deletion of the Km<sup>R</sup> cassette from the &#x00394;hfq::Km<sup>R</sup> mutant, pBZs1 was electroporated. A Sm<sup>R</sup>Ap<sup>R</sup>Km<sup>R</sup> transformant colony was grown overnight at 30 &#x000b0;C in a LB broth supplemented with Ap, spread on LB + Ap agar plates, and incubated for 24 h at 30 &#x000b0;C. Then, the colonies were individually tested for the loss of the Km<sup>R</sup> gene and the pBZs1 plasmid on LB + Ap, LB + Km, and LB + Sm plates. The Km<sup>S</sup> &#x00394;hfq strains were tested by colony PCR using the primer pair hfqseqfor&#x02013;hfqseqrev. The &#x00394;hfq mutant EMA strain was generated according to [<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>]. The 769-bp upstream and the 617 bp downstream region of the hfq gene of EMA were amplified with primer pairs hfq_up-for-Bam-hfq_up-rev and hfq-EMA_down-for-hfq_down-rev-Sac, respectively. The two amplicons were assembled in the following PCR: The assembled amplicon was purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare), digested with BamHI and SacI, and ligated into the BamHI-SacI site of pBluescript II SK(+) (pBZS13). After sequencing, the BamHI-SacI fragment from pBZS13 was transferred into the BamHI-SacI site of the R6K&#x003b3;-based plasmid pBZs12, leading to the SacB-bearing mobilizable recombination vector pBZs17. The recombination vector pBZs17 was then mobilized into EMA from <italic toggle="yes">E. coli</italic> S17-1 &#x003bb; pir. The ON culture of S17-1 &#x003bb; pir/pBZs17 was 50&#x000d7; diluted with a fresh LB broth supplemented with Km and Sm and grown 3 h to OD600~0.5, while the EMA recipient was grown in LB + Ap ON to OD600~1.0. where 0.1 mL of donor and 1 mL of recipient cultures were mixed, centrifuged, and washed twice with 0.9% NaCl solution, then spread onto LB agar plates. After 4 h of incubation at 30 &#x000b0;C, the bacterial lawn was resuspended in a 3 mL 0.9% NaCl solution, and the cells were centrifuged and spread onto LB + KmAp agar plates. After four days of incubation at 30 &#x000b0;C, the Km-Gm-Ap-resistant recombinant colonies were tested by colony PCRs using primer pairs EMAhfqseqfor-trn5neo3 and pUCfor24-hfqseqrev. To gain &#x00394;hfq recombinants, the EMA::pBZs17 strain was grown for 18 h at 30 &#x000b0;C in LB + Ap broth, and 50, 100, and 200 &#x003bc;L of the culture was spread onto LB + Ap + 5% sucrose agar plates. After 48 h incubation at 30 &#x000b0;C, the individual SacR colonies were tested for KmS and GmS phenotypes; then, the appropriate colonies were tested by colony PCR using primers EMAhfqseqfor and hfqseqrev. To verify the <italic toggle="yes">hfq</italic> deletion, the amplicon was sequenced.</p></sec><sec id="sec2dot3dot2-antibiotics-12-01462"><title>2.3.2. Bioassay of the Anti-Microbial Activities of Wild-Type and <italic toggle="yes">hfq</italic>(del) Mutants of EMA and EMC</title><p>The bioassays were carried out in 96-well (8 rows and 12 columns) tissue culture plates, in 200 &#x003bc;L volumes, containing 95 &#x000b5;L Mueller&#x02013;Hinton liquid media, 100 &#x000b5;L cell-free respective CFCM, and 5 &#x000b5;L of overnight LB cultures of the respective test organisms. Each test was carried out in duplicates in the following way: rows AB contained 100 &#x000b5;L wild-type CFCMs, 95 &#x000b5;L Mueller&#x02013;Hinton (MH) media, and 5 &#x000b5;L of stationary phase-test organisms from 37 &#x000b0;C overnight cultures in each hole. Rows C and D contained 100 &#x000b5;L of the <italic toggle="yes">hfq</italic>-del mutant CFCMs of the same species (EMA or EMC), 95 &#x000b5;L Mueller&#x02013;Hinton (MH) media, and 5 &#x000b5;L of stationary phase culture of the respective test organism (from 37 &#x000b0;C overnight cultures) in each hole. Row E: 100 &#x000b5;L wild-type CFCMs, 100 &#x000b5;L Mueller&#x02013;Hinton liquid (MH) media. Row F: 100 &#x000b5;L of the <italic toggle="yes">hfq</italic>-del mutant CFCMs of the same species (EMA or EMC), and 100 &#x000b5;L of Mueller&#x02013;Hinton (MH) media. Row G: 195 &#x000b5;L of 50% Mueller&#x02013;Hinton (MH) media + 5 &#x000b5;L of stationary phase test organisms (from 37 &#x000b0;C overnight cultures) in each hole. Row H: Row G: 200 &#x003bc;L of 0% Mueller&#x02013;Hinton (MH) media and 5 &#x000b5;L of stationary phase test organisms (from 37 &#x000b0;C overnight culture) in each hole.</p></sec></sec><sec id="sec2dot4-antibiotics-12-01462"><title>2.4. Statistical Analysis</title><p>ANOVA was carried out using the respective propositions of SAS 9.4 (see Acknowledgment section). The significant differences (&#x003b1; = 0.05) between treatment means were assessed using the least significant difference (LSD).</p></sec></sec><sec sec-type="results" id="sec3-antibiotics-12-01462"><title>3. Results</title><sec id="sec3dot1-antibiotics-12-01462"><title>3.1. Results on Anti-Leishmanial Potential</title><p>Anti-leishmanial activities of the cell-free conditioned media (CFCM) of three species of the entomopathogenic&#x02013;nematode&#x02013;symbiont bacterium genus <italic toggle="yes">Xenorhabdus</italic>, <italic toggle="yes">X. budapestensis</italic> sp. nov (Lengyel) DSM16342 (T); <italic toggle="yes">X. szentirmaii</italic> sp. nov. (Lengyel) DSM16338 (T) and; <italic toggle="yes">X. innexii</italic> sp. nov., (Lengyel) DSM16336 (T), termed EMA, EMC, and EMK, respectively, were determined and compared with antibacterial and antifungal potential. Each of the three (EMA, EMC, and EMK) examined CFCM showed significant anti-leishmanial activities, but EMA and EMC exerted stronger anti-microbial potential in general than EMK. Data are summarized in <xref rid="antibiotics-12-01462-t001" ref-type="table">Table 1</xref>.</p><p>Each of the three CFCMs strongly antagonized each of the tested clinical isolates of Gram-positive (methicillin-sensitive (MSSA), and -resistant (MRSA) <italic toggle="yes">St. aureus</italic>) and Gram-negative (<italic toggle="yes">F. novicida</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. typhimurium</italic>, as well as <italic toggle="yes">P. aeruginosa</italic>) bacteria and a clinical isolate of <italic toggle="yes">C. albicans</italic> (<xref rid="antibiotics-12-01462-t001" ref-type="table">Table 1</xref>).</p><p>As for the molecular sizes of the active natural fractions of the CFCM, interestingly, the anti-microbial activity against all microbes was retained in different size fractions of EMA (below 3 kDa) and EMC (above 3 kDa), indicating differences in the sizes of the active compounds in the different CFCMs. Autoclaved CFCM samples of EMA and EMC were as active as the native ones. As for EMK, only native CFCM samples were tested. The results demonstrated the thermostability of the active components in CFCM of EMA and EMC since autoclaving these samples did not affect the anti-microbial activity against any of the organisms. Interestingly, the anti-microbial activity of EMC, but not EMC, was susceptible to proteinase K (OK) inactivation. This suggests that the active compound (s) in EMC are proteinaceous, whereas in EMK, they are not. None of the CFCMs were toxic to J774 macrophages under the conditions in our study.</p></sec><sec id="sec3dot2-antibiotics-12-01462"><title>3.2. Antimicrobial Potential of EPB CFCM on the Prokaryotic and the Eukaryotic Partner of the H. meleagridis/E. coli Monoxenic Culture </title><p>Each CFCM was tested on <italic toggle="yes">H. meleagridis</italic> cells, which (as discovered by [<xref rid="B26-antibiotics-12-01462" ref-type="bibr">26</xref>]) can in vitro be cultured as monoxenic culture with <italic toggle="yes">E. coli</italic> DH5&#x003b1; cells, only. Consequently, the anti-Gram-negative bacterial activities were also determined.</p><sec><title>Antibacterial Potential of EPB CFCM on the Prokararyotic Partner </title><p>To see if the NR-AMP molecules were produced by strong AMP-producing EPB species, the anti-histomonal potential CFCMs from four different cultures were compared.</p><p>The <italic toggle="yes">Photorhabdus</italic> data are presented in <xref rid="antibiotics-12-01462-f001" ref-type="fig">Figure 1</xref> (effects on <italic toggle="yes">Histomonas</italic>) and <xref rid="antibiotics-12-01462-t002" ref-type="table">Table 2</xref> (effects on <italic toggle="yes">Escherichia coli</italic> DH5&#x003b1;) cells. The results indicated that there is no difference between the anti-microbial/anti-<italic toggle="yes">histomonal</italic> potential of the colony color variants, as both exerted equally strong effects on both partners of the monoxenic culture. In the cultures supplemented with either the red or the yellow colony color variants of TT01, CFCM, the cell propagation ceased, and the <italic toggle="yes">Histomonas</italic> cells&#x02014;earlier or later&#x02014;died.</p><p>From <xref rid="antibiotics-12-01462-f001" ref-type="fig">Figure 1</xref> and <xref rid="antibiotics-12-01462-t002" ref-type="table">Table 2</xref>, we concluded that the tested CFCM of each of the two colony-color variants of the EPB <italic toggle="yes">P. luminescence</italic> exerted cytotoxic activity not only on the prokaryotic (<italic toggle="yes">E. coli</italic> DH5&#x003b1;) but also on the eukaryotic <italic toggle="yes">H. meleagridis</italic> Turkey/Austria/2922-C6/0 pathogen as well. Although thie experimental was set up was scheduled for trying to distinguish between the reasons for the death of the CFCM-treated <italic toggle="yes">Histomonas</italic> cells: whether they died by direct anti-protozoal effects of the EPB-released (&#x0201d;CFCM-born&#x0201d;) AMPs, or by the indirect consequences of the death of their mutualistic prokaryote partner <italic toggle="yes">E. coli</italic> DH5@ cells, these experimental results does not allow to take this kind of distintion.</p><p>The growth curve of the monoxenic culture from the non-supplemented (that is, only FKS-containing M199) control media (green) could be characterized as performing a perfect log phase after a moderate growth period. It starts at 24 h and reaches a peak between 48 and 72 h, after which it declines. The growth curve of the monoxenic culture grown in the &#x0201c;completely supplemented&#x0201d; M199 control media (blue) can be characterized by a log phase that starts right after the start of incubation (at 0 h), reaches a peak at 48 h, and then rapidly declines. Each of the exogenous EPB CFCM resulted in reduced <italic toggle="yes">Histomonas</italic> cells. The CFCM of the red variant acted immediately, while the yellow variants acted after 24 h. Even in the latter case, the size &#x0201c;growth peak&#x0201d; at 24 h was less than half of the 4 h value of the respective control cultures. As expected, the CFCM of each colony color variant almost totally killed all the cells of the <italic toggle="yes">EMA</italic> and monoxenic accompanying prokaryotic species <italic toggle="yes">E. coli</italic> DH5 alpha (<xref rid="antibiotics-12-01462-t002" ref-type="table">Table 2</xref>).</p></sec></sec><sec id="sec3dot3-antibiotics-12-01462"><title>3.3. Anti-Microbial Activities of the hfq(del) Mutants EMA and EMC</title><p>We have constructed hfq-del regulatory mutants similar to those of [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>] (Bode et al., 2019) from both EMA and EMC strains. The relevant publication is in preparation and the method that we elaborated as a modified version of the original one is given in <xref rid="app2-antibiotics-12-01462" ref-type="app">Appendix A</xref>. We then bioassayed the anti-microbial activities of the respective CFCMs on several targets. We intend to apply the recently discovered and ingenious method called easyPACId [k1] to identify antiprotozoal compounds in the future, similar to the work by the Turkish team of Prof. Selcuk Hazir and his associates at Menderes University in Ankara, Turkey [<xref rid="B83-antibiotics-12-01462" ref-type="bibr">83</xref>]. This technique has been discovered and elaborated by Edna Bode and her associates in Frankfurt, Germany [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>]. Briefly, &#x02206;hfq mutants of two studied EPB bacterial species <italic toggle="yes">X. budapestensis</italic> and <italic toggle="yes">X. szentirmaii</italic> were constructed, and then, the CFCMs of the wt and hfq mutants were used to test different pathogen organisms. However, before obtaining that, we intend to forecast the limitations of the potential use of this approach. To learn how this influences the reproducibility of the method, we tested the anti-microbial potential of the hfq mutant of both EMA and EMC species, and the data are presented in <xref rid="antibiotics-12-01462-t003" ref-type="table">Table 3</xref>, <xref rid="antibiotics-12-01462-t004" ref-type="table">Table 4</xref> and <xref rid="antibiotics-12-01462-t005" ref-type="table">Table 5</xref>.</p><p>These data indicate that the extremely strong anti-Gram-positive potential of the EMA strain is likely, but probably not exclusively, under the control of the <italic toggle="yes">hfq</italic>-govern genetic regulation [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>]. The anti-Gram-positive antibacterial potential of EMC is stronger than the anti-Gram-negative potential but, in comparison to that of the EMA, is weaker. Note that the EMC-resistant Gram-positive species are not the same as those resistant to the antimicrobials present in the CFCM of the <italic toggle="yes">hfq</italic>-del regulatory mutant of EMA. To see how the intraspecific variability modifies the picture, we compared the resistance/sensitivity patterns of different geographical isolations of the unambiguously EMA-sensitive Gram-positive bacterium species <italic toggle="yes">Paeibacillus larvae</italic> [<xref rid="B96-antibiotics-12-01462" ref-type="bibr">96</xref>]. The <italic toggle="yes">P. larvae</italic> is a rapidly spreading deadly pathogen organism for honey bee larvae, so it is a significant pest of agricultural significance.</p><p>These data indicate that although the <italic toggle="yes">P. larvae</italic> species are uniformly and unambiguously sensitive to the anti-microbial(s) present in the CFCM of the EMA wild-type strain, there is a significant intraspecific variability concerning partly the resistance//sensitivity issue to EMC-produced antimicrobials, partly resistance/sensitivity issue to the antibiotic potential of EMA hfq-del regulatory mutants. These data are of key importance when drawing our conclusion concerning the usefulness and the limitation of the potential use of the easyPACId [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>] approach in our future research. These data also confirm that the extremely strong anti-Gram-positive potential of the EMA strain likely, but probably not exclusively, is under the control of the <italic toggle="yes">hfq</italic>-govern genetic regulation [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>]. As for the anti-histomonal studies, we sum them up in the following way.</p><p>In <xref rid="antibiotics-12-01462-f002" ref-type="fig">Figure 2</xref>, one can see the difference between the colonies of the wild type and the <italic toggle="yes">hfq</italic>-(the regulatory mutant of the <italic toggle="yes">X. szentirmaii</italic> DSM 16338 (EMC)). The spectacular physical difference is presented in the wild-type, left A, and the mutant, right B.</p></sec></sec><sec sec-type="discussion" id="sec4-antibiotics-12-01462"><title>4. Discussion</title><p>When planning experiments aimed at applying AMPs against eukaryotic (for instance, anti-protozoal) pathogens, we have to take into consideration that the strategy of designing antiprotozoals to control eukaryotic parasites (pathogens) must be different from that of designing antimicrobials to control prokaryotic pathogens [<xref rid="B97-antibiotics-12-01462" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-12-01462" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-12-01462" ref-type="bibr">99</xref>]. The targetable intracellular structures of a eukaryotic parasite (pathogen) biochemically might be similar to some intracellular structures of vital functions in the eukaryote host to be protected. </p><p>As for our <italic toggle="yes">H. meleagrididis</italic> exeriments, we worked in a monoxenic system where prokaryotic and eukaryotics cells coexisted. We found that both the prokaryotic and the eukaryotic cells died when EPB CFCM were added in th right concentration.</p><p>The question is, however, that what was the primary reason for the death of the <italic toggle="yes">H. meleagridis</italic> cells. They might die (1) because their procaryote mutualistic partner died; (2) they might be killed by a direct antiprotist activity of any (or more) AMP molecules of the EPB CFCMs; or (3) the two killing effects cumulated. Unfortunately, these published experiments cannot give an unambiguous answer to that question. We hope for the answer from our future experiments when we intend to use CFCMs from double (easyPACId) mutants (with <italic toggle="yes">hfq</italic>-deletion and exchanged (re-activated) promoter of only one AMP-responsible operon. We will search for some which is harmless to prokaryotic partner but kill <italic toggle="yes">H. meleagridis</italic> cells selectively). It is true, that the peptides killed the mutualistic (<italic toggle="yes">E. coli DH5@</italic>) bacteria, which itself could be considered as an explanation of the death of the <italic toggle="yes">H. meleagridis</italic> cells. It is also true, that from our experiments no proof supports the idea that histomonads were killed directly. But we also have evidence that CFCM contains active anti-protist active components as well, (see the Leishmania donovanii data from this study or the published results of the Bode group and others), so the only question is what of these compounds is capable of (in lucky case, selectively) killing <italic toggle="yes">H. meleagridis</italic>. This is what we intend to learn from our future easyPACId mutant experiments.</p><p>This paper is about the anti-protist potential of anti-microbial compounds produced by entomopathogenic bacterium species (EMA, EMC, and EMK <italic toggle="yes">Photorhabdus luminescens</italic> TT01) [<xref rid="B6-antibiotics-12-01462" ref-type="bibr">6</xref>,<xref rid="B28-antibiotics-12-01462" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-12-01462" ref-type="bibr">29</xref>,<xref rid="B93-antibiotics-12-01462" ref-type="bibr">93</xref>], the obligate symbionts of certain entomopathogenic&#x02013;nematodes (EPN). In laboratory in vitro conditions they release their products into their conditioned culture media (CFCM) in vitro. The chemical nature of these antimicrobials is oligo-peptide. However they are non-ribosomal anti-microbial peptides (NR-AMPs), which means that they are enzymatically synthesized through more than one step in their respective biosynthetic pathways. Those genes encoding for the enzymes forming the respective biosynthetic pathway of given NR-AMP are clustered in a single operon [<xref rid="B100-antibiotics-12-01462" ref-type="bibr">100</xref>], also called biosynthetic gene complex (BGC) [<xref rid="B101-antibiotics-12-01462" ref-type="bibr">101</xref>]. One of the natural roles of the prokaryote partner in the EPN/EPB symbiosis is to protect the given monoxenic symbiotic association in a given polyxenic milieu, producing a chemical toolkit (e.g., a particular set of NR-AMPs) providing competitiveness against the prokaryotic and eukaryotic competitors, including protists. The biosynthesis of the given sets of these effective antimicrobials is synchronized by a unique, genuine hierarchical genetic regulation mechanism called primary-secondary phase shift [<xref rid="B71-antibiotics-12-01462" ref-type="bibr">71</xref>] with the <italic toggle="yes">hfq</italic> gene on the top [<xref rid="B74-antibiotics-12-01462" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-12-01462" ref-type="bibr">75</xref>,<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-12-01462" ref-type="bibr">78</xref>]. In the laboratory liquid culture conditions (as well as in the active symbiotic stage), these compounds are produced abundantly, providing an inexhaustible &#x0201c;gold mine&#x0201d; for the anti-microbial searching scientist. The bioassays of the CFCMs are the tools to find the best sources and optimize the culture conditions. We found that those strains (EMA and EMC) which were discovered and further developed not only by our international team of a &#x0201c;laboratory without walls&#x0201d; in those famous laboratories of Maxime Gualtieri in France and Helge Bode in Germany, proving that these two strains are probably best found so far. In addition, other laboratories are probably really excellent sources. The data presented here on anti-leishmanial and anti-histomonal potentials seem to confirm this conclusion. The next step is to find a way to obtain mutants, not &#x0201c;genetically manipulated&#x0201d;, but mutant strains which produce only single NR-AMP molecules instead of a bunch of them. The method to do that was recently discovered in the Bode laboratory [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-12-01462" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-12-01462" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-12-01462" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-12-01462" ref-type="bibr">83</xref>]. We demonstrate here that we have started this project as well by constructing and characterizing <italic toggle="yes">hfq</italic>-del mutants from both EPB species EMA and EMC.</p><p>Our larger scope is to benefit from the existence of NR-AMP amongst the metabolites of our EPB bacteria. In other terms, our goals are to beat target pathogens, including prokaryotic pathogenic and zoonic bacteria, and eukaryotic parasites and pathogens of different taxa, which are important from the aspects of importance for animal and human health.</p><p>We are keenly interested in exploring whether the anti-microbial activity of NR-AMP of EMA and EMC can be developed as chemotherapeutic agents to treat protozoa such as the intracellular parasite <italic toggle="yes">Leishmania</italic> [<xref rid="B37-antibiotics-12-01462" ref-type="bibr">37</xref>] and the extracellular avian pathogen <italic toggle="yes">H. gallinarum</italic> [<xref rid="B97-antibiotics-12-01462" ref-type="bibr">97</xref>]. Both of these flagellated protozoa have been demonstrated to have unique and efficient resistance mechanisms to other anti-parasitic agents and require the development of additional effective agents. <italic toggle="yes">Leishmania</italic> spp. is particularly problematic in light of its sophisticated resistance mechanisms, but it is also an excellent model for analyzing the mechanisms of drug resistance in eukaryotes [<xref rid="B98-antibiotics-12-01462" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-12-01462" ref-type="bibr">99</xref>]. Our research conception is that we think that some <italic toggle="yes">Xenorhabdus</italic> CFCM molecules (i.e., phenazine, fabclavine, or other molecules) may be selectively capable of dysregulating eukaryotic cell functions and stimulating apoptosis in protozoa without affecting the host [<xref rid="B100-antibiotics-12-01462" ref-type="bibr">100</xref>]. From an application point of view, the development of natural compounds as anti-protozoal requires several aspects to be taken into consideration: (A) the anti-protozoal potential; (B) the durability, thermotolerance, and bioavailability; and (C) cytotoxicity, and unwanted side effects, especially if target organisms are eukaryotic pathogens. We have demonstrated that <italic toggle="yes">Xenorhabdus</italic> CFCM has broad-spectrum anti-protozoal activity against several human microbial pathogens. The key issue is identifying the specific active molecules in a complex mixture of potential anti-microbial molecules. The CFCMs of all three <italic toggle="yes">Xenorhabdus</italic> species were all active against <italic toggle="yes">Leishmania</italic> promastigotes in our experiments, but interestingly, none were active against <italic toggle="yes">Trypanosoma cruzi</italic> epimastigotes. Other researchers [<xref rid="B83-antibiotics-12-01462" ref-type="bibr">83</xref>] found that EMA and EMK CFCMs were equally efficient against both <italic toggle="yes">Leishmania</italic> and <italic toggle="yes">Trypanosoma</italic>. In that study, they found that <italic toggle="yes">X. budapestensis</italic>, <italic toggle="yes">X. cabanillasii</italic>, <italic toggle="yes">X. hominickii</italic>, <italic toggle="yes">X. indica</italic>, <italic toggle="yes">X. innexii</italic>, and <italic toggle="yes">X. stockiae</italic> supernatants caused 100% mortality at the highest tested concentration (10%) against the promastigote form of <italic toggle="yes">L. tropica</italic>. No differences occurred between this treatment group and the positive control (<italic toggle="yes">p</italic> &#x0003e; 0.05) using N-methyl meglumine. There are several possible explanations for the differences between our findings and those of the Turkish team. For instance, the two studies used different strains of <italic toggle="yes">T. cruzi</italic>. In addition, there are differences in the experimental methods used between the two studies. In the case of the differential susceptibility of <italic toggle="yes">L. amazoennsis</italic> and <italic toggle="yes">T. cruzi</italic> (Brazil strain), it is likely due to differences in the surface compositions between the two parasites that lead to differential disruption of the cell membrane and/or intracellular penetration to act on specific subcellular targets. We focus on EMA and EMC species. We compared the anti-microbial potential of each of the used <italic toggle="yes">hfq</italic>-del mutants before using them as the source of double mutants producing single NR-AMPs. Our data in <xref rid="antibiotics-12-01462-t003" ref-type="table">Table 3</xref>, <xref rid="antibiotics-12-01462-t004" ref-type="table">Table 4</xref> and <xref rid="antibiotics-12-01462-t005" ref-type="table">Table 5</xref> show that the anti-microbial activities of the <italic toggle="yes">hfq</italic>-del mutants can have enhanced anti-microbial activity not present in the wild-type stains. This may not be quite surprising considering that approximately 7.5% of the total genes in <italic toggle="yes">Xenorhabdus</italic> bacteria are dedicated to secondary metabolite biosynthesis, and probably most of these products are NR-AMPs. With an average 2.4 Mb-genome size of <italic toggle="yes">Xenorhabdus</italic> and a 1 kb locus size with about 10 ORFs per operon, there are 2400 genes and 240 respective operons (BGS) per genome. It is comparable with that of <italic toggle="yes">Staphylococcus</italic>, which has about 225 operons. According to the data accumulated, only about a dozen of biosynthetic anti-microbials have been discovered. In our lab, we intend to work with about 12 operons, responsible for the biosynthesis of 12 NR-AMPs in EMC, and operons which are responsible for 3 NR_AMPs in EMA under <italic toggle="yes">hfq</italic> regulations.</p><p>However, we cannot rule out that there are several other operons encoding for the synthesis of additional anti-microbial compounds, which are not under hfq control. In the future, we intend to establish and analyze RNA-seq from our wild-type stains and their <italic toggle="yes">hfq</italic> mutants. We hypothesize that the situation is somewhat simpler since the hfq likely regulates a well-defined group of operons providing the genetic machinery for the so-called &#x0201c;primary-secondary phase shift&#x0201d; [<xref rid="B72-antibiotics-12-01462" ref-type="bibr">72</xref>] (or &#x0201c;phenotypic phase variation&#x0201d;, the term of Professor S. A. Forst), which describes that only a relatively small set of natural products (NP) are anti-microbial synthetic genes. Toxicity studies using J774 macrophages [<xref rid="B66-antibiotics-12-01462" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-12-01462" ref-type="bibr">67</xref>] have indicated that only the CFCM of EMA was able to cause significant mortality of these cells. In contrast, the CFCMs of EMC or EMK had no effect. This experiment confirmed our previous unpublished observations that EMA exerts stronger cytotoxicity on a range of eukaryotic cells, which may cause limitations concerning future medical applications. However, this selective cytotoxicity may provide an option to select for and find specific CFCMs against different eukaryotic parasites of different animal and plant hosts. Interestingly, our studies with J774 cells and the CFCMs of EMA, EMC, and EMK did not show toxicity. These differences may be related to different experimental methods or differences in the bacterial and cell types used.</p><p>Overall, in light of the availability of few agents for the treatment of leishmaniasis and the increasing incidence of development resistance, there is a demand for new agents [<xref rid="B100-antibiotics-12-01462" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-12-01462" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-12-01462" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-12-01462" ref-type="bibr">103</xref>]. Moving forward, drug discovery will be based on complete genome sequencing of multiple strains, utilization of CRISPR/Cas9 technology for gene inactivation, in vivo, and bioluminescence-based imaging together with high-throughput analysis of compounds [<xref rid="B44-antibiotics-12-01462" ref-type="bibr">44</xref>]. As for the results in the control (bacterium, fungi, and other strains), previous studies have identified several anti-microbial molecules in the CFCM of <italic toggle="yes">Xenorhabdus</italic>, including fabclavine [<xref rid="B25-antibiotics-12-01462" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-12-01462" ref-type="bibr">26</xref>]. This strange metabolite polypeptide/polyketide hybrid molecule is synthesized via non-ribosomal peptide synthesis. Many different-sized derivatives of fabclavines can be produced by <italic toggle="yes">X. szentirmaii</italic> [<xref rid="B80-antibiotics-12-01462" ref-type="bibr">80</xref>] and can vary between entomopathogenic&#x02013;nematode&#x02013;symbiont (<italic toggle="yes">Xenorhabdus</italic>, <italic toggle="yes">Photorhabdus</italic>) bacterium species [<xref rid="B80-antibiotics-12-01462" ref-type="bibr">80</xref>] (Wenski et al., 2019). These have a wide-ranging anti-microbial activity against various microbes [<xref rid="B29-antibiotics-12-01462" ref-type="bibr">29</xref>]. Several other anti-microbial molecules are known to be produced by different EPB species and released into their CFCMs. Xenofuranone A and B [<xref rid="B104-antibiotics-12-01462" ref-type="bibr">104</xref>], cabanillasin [<xref rid="B105-antibiotics-12-01462" ref-type="bibr">105</xref>], PAX peptides [<xref rid="B106-antibiotics-12-01462" ref-type="bibr">106</xref>], odilorhabdins [<xref rid="B107-antibiotics-12-01462" ref-type="bibr">107</xref>], cyclic depsipeptides (xenematides, F and G), anti-oomycete peptides [<xref rid="B108-antibiotics-12-01462" ref-type="bibr">108</xref>], novel anti-microbial peptides [<xref rid="B109-antibiotics-12-01462" ref-type="bibr">109</xref>], xenortide [<xref rid="B110-antibiotics-12-01462" ref-type="bibr">110</xref>], xenortides, rhabdopeptided/xenortide-like peptides [<xref rid="B111-antibiotics-12-01462" ref-type="bibr">111</xref>], other rhabdopeptides [<xref rid="B112-antibiotics-12-01462" ref-type="bibr">112</xref>], and szentiamid [<xref rid="B113-antibiotics-12-01462" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-12-01462" ref-type="bibr">114</xref>] have been discovered in the last ten years in different <italic toggle="yes">Xenorhabdus</italic> species.The proper approach is the easyPACId method, based on the latest information on the highest organization level of gene regulation in bacteria [<xref rid="B115-antibiotics-12-01462" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-12-01462" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-12-01462" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-12-01462" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-12-01462" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-12-01462" ref-type="bibr">120</xref>]. Whether any of them can be considered a potential anti-histomonal drug candidate will be learned if we had a chance to screen both the single mutant <italic toggle="yes">hfq-</italic>del stains of EMA and EMC.</p></sec><sec sec-type="conclusions" id="sec5-antibiotics-12-01462"><title>5. Conclusions</title><p>Conclusions could be drawn from this study if we see the aims and the results along with the following aspects:<list list-type="order"><list-item><p>Perspectives of EPN/EPB symbiotic associations as abundant sources of AMPs, and we feel that the present publication provides some new idea into this direction</p></list-item><list-item><p>The comparative aspects of biosynthetic (non-ribosomal templated) and primary gene-product AMPs from drug potential aspects; and this publication drew the attention of the reade tosome complementary aspects.</p></list-item><list-item><p>The strategic aspects of controlling selected eukaryotic pathogens; we concluded the NR-AMPS have more option of becoming potential drugs to handle this issue.</p></list-item><list-item><p>The scientific and industrial aspects of the recently discovered hierarchical regulatory systems following signal integration provide great metabolic versatility that results in excellent adaptability and metabolic optimization in antibiotic-producing bacteria [<xref rid="B99-antibiotics-12-01462" ref-type="bibr">99</xref>], like EPBs.</p></list-item></list></p><p>We would like to emphasize the actual importance of this research when concluding that the delineation of specific anti-microbial products in CFCM can now be achieved using the &#x0201c;easyPACId&#x0201d; approach (easy promoter-activated compound identification), which takes advantage of the alteration of regulation of coordinate gene clusters whose products are responsible for their biosynthesis [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>]. We are convinced that this discovery may revolutionize the <italic toggle="yes">Xenorhabdus</italic>/<italic toggle="yes">Photorhabdus</italic> research, which in the age of multidrug resistance seems important. The point is that the operation of the different biosynthetic gene clusters BGCs (that is, operons) is synchronous, and their regulation is coordinated [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>] by the gene encoding the RNA chaperone, Hfq [<xref rid="B79-antibiotics-12-01462" ref-type="bibr">79</xref>]. The experimental system is based on the option of manipulation of the regulatory gene <italic toggle="yes">hfq</italic> [<xref rid="B100-antibiotics-12-01462" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-12-01462" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-12-01462" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-12-01462" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-12-01462" ref-type="bibr">104</xref>] of the respective species. The regulatory mutant strain does not produce any biosynthetic AMP, but the respective individual promoters upstream of the respective biosynthetic gene cluster can be changed to inducible promotors, and this recombination will produce only a single respective AMP molecule. This provides an option of obtaining bacteria that produce only one single AMP molecule. The NR-AMP molecules have similar advantages to traditional antibiotics as the ribosomal templated AMPs, that is, the different pools of resistance genes with different motility patterns and collateral sensitivity, as well as molecular versatility. The advantage of the natural abundance in AMPs provided by the coevolutionary pattern of EPN/EPB symbiotic association may provide ammunition usable against MDR pathogens for a long time. This research line is further facilitated by the completed genome sequencing of several <italic toggle="yes">Xenorhabdus</italic> species, including <italic toggle="yes">X. szentirmaii</italic> [<xref rid="B121-antibiotics-12-01462" ref-type="bibr">121</xref>] and <italic toggle="yes">X. budapestensis</italic> [<xref rid="B122-antibiotics-12-01462" ref-type="bibr">122</xref>], making possible the identification of the promoter regions of each biosynthetic gene cluster (BGC, operon). Despite demonstrating the efficacy of vaccination in an experimental setting [<xref rid="B55-antibiotics-12-01462" ref-type="bibr">55</xref>,<xref rid="B58-antibiotics-12-01462" ref-type="bibr">58</xref>,<xref rid="B123-antibiotics-12-01462" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-12-01462" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-12-01462" ref-type="bibr">125</xref>] no vaccine is yet commercially available. Therefore, and in addition to various other attempts, alternative chemotherapeutic solutions ares justified and the application potential of AMPs [<xref rid="B126-antibiotics-12-01462" ref-type="bibr">126</xref>] seems a realistic idea.</p><p>Creating bacterial mutants that synthesize individual anti-microbial products into CFCM can facilitate their identification, purification, and bioassays of anti-microbial activity [<xref rid="B82-antibiotics-12-01462" ref-type="bibr">82</xref>] and finally their potential application.</p></sec></body><back><ack><title>Acknowledgments</title><p>A special thanks to special thanks to Jun Fu (Helmholtz International Lab for Anti-Infectives, Shandong University, Helmholtz Institute of Biotechnology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao, China), Tao Sun and Jia Yin (Hunan Provincial Key Laboratory of Animal Intestinal Function and Regulation, College of Life Sciences, Hunan Normal University, Changsha, China) for providing us the plasmid pSC101-BAD-plu2934/2935/2936-gamma-amp. The use of these plasmids was essential for the success of getting hfq-del mutants from EMA and EMC. This work has been performed in a &#x0201c;laboratory without walls&#x0201d; that is within a frame of voluntary international research cooperation in Budapest. Despite his coauthrship, we thank the Head of the Department of Genetics at E&#x000f6;tv&#x000f6;s University, for welcoming us back to the project and supporting it financially and morally as well as technically. (This project was born 20 years earlier in that department.). In Vienna, at the Clinic for Poultry and Fish Medicine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine (Vetmeduni, Vienna, Austria), we would like to express thanks and appreciation not only for their professional technical but also the intellectual help to the whole research team of the Hess laboratory, especially to Aziza Amin, and Irina Prokofieva in Keszthely, at the Institute of Physiology and Nutrition, Georgikon Campus of Hungarian University of Agriculture and Life Sciences, (MATE), Hungary, where the previous (and probably the future) in vivo feeding experiments have been going on. We express thanks and appreciation not only for their professional technical but also for the intellectual help of the Dublecz team. Many thanks for the professional and financial help in the molecular and bioinformatical work in the team of J&#x000e1;nos Kiss (especially M&#x000f3;nika Szab&#x000f3;). We would like to express the invaluable help in the laboratories of Michael Klein, Joe Hogan, and Brad McGwire concerning the <italic toggle="yes">Leishmania</italic> work in Ohio.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-antibiotics-12-01462"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/antibiotics12091462/s1">https://www.mdpi.com/article/10.3390/antibiotics12091462/s1</uri>, Material S1: <italic toggle="yes">Histomonas</italic> Experiments. </p><supplementary-material id="antibiotics-12-01462-s001" position="float" content-type="local-data"><media xlink:href="antibiotics-12-01462-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.F., M.H., B.S.M., A.S., T.V. and J.K.; investigation, A.F., Z.B., J.K., M.M.K. and P.G.; methodology, J.K., L.M., M.G.K. and E.T.; data curation, L.P.; formal analysis, C.H.; funding acquisition, K.D., M.G.K., T.V. and M.H.; project administration, T.V. and M.H.; resources, T.V. and M.H.; visualization, L.M.; Supervision, L.F., M.G.K., T.V. and M.H.; validation, C.H. and K.D.; writing&#x02014;original draft, A.F. and M.G.K.; writing&#x02014;review and editing, C.H., M.H., J.K., B.S.M., E.T., T.V., L.F. and L.M. All authors have read and agreed to the published version of the manuscript. </p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All of the data are available from the corresponding author. All data generated from this study are included in this article, and some information in the <xref rid="app1-antibiotics-12-01462" ref-type="app">Supplementary Materials</xref> is strongly inseparable from information published in our previous paper [<xref rid="B6-antibiotics-12-01462" ref-type="bibr">6</xref>].</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. We sincerely consider those fellow scientists working in the same field as potential cooperators rather than competitors. Furthermore, the authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><app-group><app id="app2-antibiotics-12-01462"><title>Appendix A</title><sec id="secAdot1-antibiotics-12-01462"><title>Appendix A.1. Experimental Details of the Construction of hfq(del) Mutants of EMA and EMC Strains</title><p>The &#x00394;<italic toggle="yes">hfq</italic> mutant EMC strain was generated according to the one-step gene inactivation method [<xref rid="B100-antibiotics-12-01462" ref-type="bibr">100</xref>]. which was adapted to <italic toggle="yes">Xenorhabdus</italic>. The &#x003bb; Red recombinase was replaced by the <italic toggle="yes">Photorhabdus luminescence</italic>-derived homolog encoded by the Plu2934/Plu2935/Plu2936 operon [<xref rid="B101-antibiotics-12-01462" ref-type="bibr">101</xref>]. The plasmid pSC101-BAD-plu2934/2935/2936-gamma-amp containing a thermosensitive pSC101-derived replication system and the Plu2934/Plu2935/Plu2936 operon with the &#x003bb; Red&#x003b3; gene under the control of ParaBAD was a kind gift from Jun Fu. Plasmids were introduced into <italic toggle="yes">X. szentirmaii</italic> (EMC) by electroporation. Electrocompetent cells were prepared for introduction of plasmids as follows: 1 mL of <italic toggle="yes">X. szentirmaii</italic> (EMC) culture grown at 30 &#x000b0;C in LB broth supplemented with Ap (150 &#x003bc;g/mL) to OD600~1.1&#x02013;1.2 was centrifuged for 30 s at 9000 rpm at 2 &#x000b0;C, then resuspended in an ice-cold wash buffer SMG (0.5 M sorbitol, 0.5 M mannitol, 10% glycerol) and centrifuged again. The washing step was repeated two times; then, the cells were resuspended in a 60 &#x003bc;L SMG buffer.</p><p>Approximately 1 &#x003bc;g of plasmid DNA purified by the Qiagen Plasmid Midi Kit according to the manufacturer&#x02019;s protocol was added to 40 &#x003bc;L electrocompetent cells. Electroporation was carried out using 2 mm gap electroporation cuvettes and BTX Electro Cell Manipulator 600 with the setting 129 ohm 24 kV/cm. Transformants were selected on LB plates supplemented with the appropriate antibiotics (Km&#x02014;120 &#x003bc;g/mL, Sm&#x02014;100 &#x003bc;g/mL, Gm&#x02014;50 &#x003bc;g/mL, and Ap&#x02014;150 &#x003bc;g/mL).</p><p>For the <italic toggle="yes">hfq</italic> KO recombination, EMC cells containing plasmid pBZs7 were grown in LB broth supplemented with Gm and Ap to a late logarithmic (OD<sub>600</sub>~1.1&#x02013;1.2) phase, then the culture was 2&#x000d7; diluted with fresh LB broth, L-arabinose was added in a final concentration of 1% and grown further in a shaker for 1.5 h at 30 &#x000b0;C. The electro-competent cells were prepared as described above. The KO PCR fragment was amplified using pKD4 template plasmid and the primers hfq_EMCdelfor and hfq_EMCdelrev. The amplicon was precipitated in 96% ethanol, dried, and resuspended in 10 mM Tris pH 8.0. For electroporation, approximately 1 &#x003bc;g of purified DNA fragment was used as described. After electroporation, cells were grown for 5 h at 30 &#x000b0;C, then spread on LB agar plates supplemented with 120 &#x003bc;g/mL Km and incubated at 30 &#x000b0;C for 2 days. The &#x00394;<italic toggle="yes">hfq</italic>::Km<sup>R</sup> recombinant was tested by colony PCRs using the primer pairs hfqseqfor-trn5neo5, rn5neo3-hfqseqrev, and hfqseqfor-hfqseqrev.</p><p>For deletion of the Km<sup>R</sup> cassette from the &#x00394;<italic toggle="yes">hfq</italic>::Km<sup>R</sup> mutant, pBZs1 was electroporated. A Sm<sup>R</sup>Ap<sup>R</sup>Km<sup>R</sup> transformant colony was grown overnight at 30 &#x000b0;C in LB broth supplemented with Ap, spread on LB + Ap agar plates, and incubated for 24 h at 30 &#x000b0;C; then, the colonies were individually tested for the loss of the Km<sup>R</sup> gene and the pBZs1 plasmid on LB + Ap, LB + Km, and LB + Sm plates. The Km<sup>S</sup> &#x00394;hfq strains were tested by colony PCR using the primer pair hfqseqfor&#x02013;hfqseqrev.</p><p>The &#x00394;<italic toggle="yes">hfq</italic> mutant EMA strain was generated according to [<xref rid="B77-antibiotics-12-01462" ref-type="bibr">77</xref>] (Aref 10) The 769 bp upstream and the 617 bp downstream region of the <italic toggle="yes">hfq</italic> gene of EMA were amplified with primer pairs hfq_upforBam-hfq_uprev and hfqEMA_downfor-hfq_downrevSac, respectively. The two amplicons were assembled in the following PCR:</p><p>Using 0.5 &#x003bc;L of the upstream and 2 &#x003bc;L of the downstream amplicons, 60 s denaturation at 94 &#x000b0;C followed by 15 cycles of 94 &#x000b0;C 20 s, 55 &#x000b0;C 30 s, and 72 &#x000b0;C for 2 min, then 0.5 &#x003bc;L of primers hfq_upforBam and hfq_downrevSac (10 &#x003bc;M each) were added and the cycling was continued for a further 35 cycles. The amplicon was purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare), digested with BamHI and SacI, and ligated into the BamHI-SacI site of pBluescript II SK(+) (pBZS13). After sequencing, the BamHI-SacI fragment from pBZS13 was transferred into the BamHI-SacI site of the R6K&#x003b3;-based plasmid pBZs12, leading to the SacB-bearing mobilizable recombination vector pBZs17.</p><p>pBZs17 was mobilized into EMA from <italic toggle="yes">E. coli</italic> S17-1 &#x003bb; pir. The ON culture of S17-1 &#x003bb; pir/pBZs17 was 50&#x000d7; diluted with fresh LB broth supplemented with Km and Sm and grown 3 h to OD600~0.5, while the EMA recipient was grown in LB + Ap ON to OD600~1.0. 0.1 mL of donor and 1 mL of recipient cultures were mixed, centrifuged, and washed twice with 0.9% NaCl solution, then spread onto LB agar plates. After 4 h incubation at 30 &#x000b0;C, the bacterial lawn was resuspended in 3 mL 0.9% NaCl solution, and the cells were centrifuged and spread onto LB + KmAp agar plates. After four days of incubation at 30 &#x000b0;C, the KmRGmRApR recombinant colonies were tested by colony PCRs using primer pairs EMAhfqseqfor&#x02013;trn5neo3 and pUCfor24&#x02013;hfqseqrev.</p><p>To gain &#x00394;<italic toggle="yes">hfq</italic> recombinants, the EMA::pBZs17 strain was grown for 18 h at 30 &#x000b0;C in LB + Ap broth, and 50, 100, and 200 &#x003bc;L of the culture was spread onto LB + Ap + 5% sucrose agar plates. After 48 h incubation at 30 &#x000b0;C, the individual SacR colonies were tested for KmS and GmS phenotypes; then, the appropriate colonies were tested by colony PCR using primers EMAhfqseqfor and hfqseqrev. To verify the hfq deletion, the amplicon was sequenced.</p><p>Restriction enzymes and DNA polymerases were purchased from Thermo Scientific. Colony PCRs were carried out using Dream Taq polymerase, while for the amplification of fragments for cloning or KO experiments, a Phusion polymerase was applied.</p><p>For maintaining the plasmids with a temperature-sensitive pSC101 replication system, growth at 30 &#x000b0;C with antibiotic selection was applied, while curing these plasmids was carried out by growth at 30 &#x000b0;C without antibiotic selection, followed by testing the resistance pattern of individual colonies for selecting plasmid-cured clones.</p><p>For cloning purposes, <italic toggle="yes">E. coli</italic> TG1 [<xref rid="B3-antibiotics-12-01462" ref-type="bibr">3</xref>] was used as a host strain. For plasmid mobilization into <italic toggle="yes">Xenorhabdus</italic>, <italic toggle="yes">E. coli</italic> S17-1&#x003bb; <italic toggle="yes">pir</italic> [<xref rid="B86-antibiotics-12-01462" ref-type="bibr">86</xref>] was applied. <italic toggle="yes">E. coli</italic> strains were routinely grown in LB at 37 &#x000b0;C with appropriate antibiotic selection. Restriction enzymes and DNA polymerases were purchased from Thermo Scientific. Colony PCRs were carried out using Dream Taq polymerase, while the amplification of fragments for cloning or KO experiments, Phusion polymerase, was applied.</p><table-wrap position="anchor" id="antibiotics-12-01462-t0A1"><object-id pub-id-type="pii">antibiotics-12-01462-t0A1_Table A1</object-id><label>Table A1</label><caption><p>Relevant features of plasmids used in this work.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevant Features</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBluescript II SK (+)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pMB1-based ApR cloning vector.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-antibiotics-12-01462" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pKD4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Km<sup>R</sup>,Ap<sup>R</sup> r6k&#x003b3;-based PCR template plasmid for one-step recombination gene-KO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-antibiotics-12-01462" ref-type="bibr">2</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBZs1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sm<sup>R</sup>,Cm<sup>R</sup>,Ap<sup>S</sup>, derivative of pCP20 [<xref rid="B1-antibiotics-12-01462" ref-type="bibr">1</xref>] containing also the <italic toggle="yes">oriT</italic> of RP4, thermo-inducible FLP recombinase expression (&#x003bb; pR::FLP), temperature-sensitive pSC101 replication system, &#x003bb; cI857, mobilization by S17-1&#x003bb; <italic toggle="yes">pir</italic> host strain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBZS7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Km<sup>R</sup>,Ap<sup>S</sup> derivative of pSC101-BAD-plu2934/2935/2936-gamma-amp [<xref rid="B88-antibiotics-12-01462" ref-type="bibr">88</xref>], L-ara-inducible expression of &#x003bb; Red recombinase homolog from <italic toggle="yes">P. luminescens</italic> and &#x003bb; Red&#x003b3; protein, temperature-sensitive pSC101 replication system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBZs12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pJQ200-SK derivative, where the SspI-NheI fragment carrying the p15A origin of replication was replaced by the ClaI-NheI fragment of pSG76-K containing the Km<sup>R</sup> gene and R6K&#x003b3; origin of replication. KmR, GmR, RP4 oriT, R6K&#x003b3; oriV, SacB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBZs17</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pBZs12 derivative, containing the assembled upstream and downstream region of the hfq gene of EMA. KmR, GmR, RP4 oriT, R6K&#x003b3; oriV, SacB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pSG76-K</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R6K&#x003b3;-based Km<sup>R</sup> replicon </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-antibiotics-12-01462" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pJQ200-SK</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A SacB-bearing p15A-based vector. GmR, RP4 oriT, p15A oriV, SacB.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B91-antibiotics-12-01462" ref-type="bibr">91</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="antibiotics-12-01462-t0A2"><object-id pub-id-type="pii">antibiotics-12-01462-t0A2_Table A2</object-id><label>Table A2</label><caption><p>Relevant features of bacterial strains used in the molecular genetics section of this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevant Features</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TG1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">supE hsd&#x00394;5 thi &#x00394;(lac-proAB) F&#x02019;[traD36 proAB+ lacIq lacZ&#x00394;M15]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-antibiotics-12-01462" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S17-1 &#x003bb;<italic toggle="yes">pir</italic></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S17-1 &#x003bb;<italic toggle="yes">pir</italic>, a &#x003bb; lysogen derivative of S17-1 (<italic toggle="yes">pro thi recA hsdR</italic> (r<sup>&#x02212;</sup> m<sup>+</sup>) Tp<sup>R</sup> Sm<sup>R</sup> Km<sup>S</sup> [&#x003a9; RP4-2-Tc::Mu-Km::Tn<italic toggle="yes">7</italic>]) expressing &#x003a0; protein from <italic toggle="yes">pir</italic> gene of R6K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-antibiotics-12-01462" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X. budapestensis DSM16342</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">wt isolate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-antibiotics-12-01462" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">X. szentirmaii</italic> DSM 16338</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">wt isolate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="antibiotics-12-01462-t0A3"><object-id pub-id-type="pii">antibiotics-12-01462-t0A3_Table A3</object-id><label>Table A3</label><caption><p>List of oligonucleotides used.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence (5&#x02032;-3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfq_EMCdelfor</td><td align="left" valign="middle" rowspan="1" colspan="1">gaaccaaaaggttcttagttaaaacaacaaaataaggaaaatatagaatgGTGTAGGCTGGAGCTGCTTC</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfq_EMCdelrev</td><td align="left" valign="middle" rowspan="1" colspan="1">aagtctccctacctatgtttttatttacttcaggtatggtcactgatttaCATATGAATATCCTCCTTAGTTC</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfqEMAseqfor</td><td align="left" valign="middle" rowspan="1" colspan="1">tgtggtcttatctcgcgggc</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfqseqfor</td><td align="left" valign="middle" rowspan="1" colspan="1">tctcatgatgagatggtttatcgtg</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfqseqrev</td><td align="left" valign="middle" rowspan="1" colspan="1">gcacaggagaaacacctgcgg</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">trn5neo3</td><td align="left" valign="middle" rowspan="1" colspan="1">tcgccttctatcgccttcttga</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">trn5neo5</td><td align="left" valign="middle" rowspan="1" colspan="1">aatagcctctccacccaagcgg</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfq_upforBam</td><td align="left" valign="middle" rowspan="1" colspan="1">aaggatccactcctggttggcggaaccatgc</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfq_uprev</td><td align="left" valign="middle" rowspan="1" colspan="1">caaagattgccccttagccattctatattttccttattttg</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfqEMA_downfor</td><td align="left" valign="middle" rowspan="1" colspan="1">caaaataaggaaaatatagaatggctaaggggcaatctttgatcgctgaataaatcagtgataatgcctgg</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hfq_downrevSac</td><td align="left" valign="middle" rowspan="1" colspan="1">aagagctctttgtcacgcagcatacggcggtc</td><td align="center" valign="middle" rowspan="1" colspan="1">this work</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pUCfor24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cgccagggttttcccagtcacgac</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-antibiotics-12-01462" ref-type="bibr">92</xref>]</td></tr></tbody></table></table-wrap></sec></app></app-group><ref-list><title>References</title><ref id="B1-antibiotics-12-01462"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;tvos</surname><given-names>L.</given-names><suffix>Jr.</suffix></name>
<name><surname>Wade</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Current challenges in peptide-based drug discovery</article-title><source>Front. Chem.</source><year>2014</year><volume>2</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.3389/fchem.2014.00062</pub-id><pub-id pub-id-type="pmid">25152873</pub-id></element-citation></ref><ref id="B2-antibiotics-12-01462"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karelson</surname><given-names>M.</given-names></name>
<name><surname>Lobanov</surname><given-names>V.S.</given-names></name>
<name><surname>Katritzky</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Quantum-Chemical Descriptors in QSAR/QSPR Studies</article-title><source>Chem. Rev.</source><year>1996</year><volume>96</volume><fpage>1027</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1021/cr950202r</pub-id><pub-id pub-id-type="pmid">11848779</pub-id></element-citation></ref><ref id="B3-antibiotics-12-01462"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gini</surname><given-names>G.</given-names></name>
</person-group><article-title>QSAR Methods</article-title><source>Methods Mol. Biol.</source><year>2022</year><volume>2425</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1960-5_1</pub-id><?supplied-pmid 35188626?><pub-id pub-id-type="pmid">35188626</pub-id></element-citation></ref><ref id="B4-antibiotics-12-01462"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cammue</surname><given-names>B.P.</given-names></name>
<name><surname>De Bolle</surname><given-names>M.F.</given-names></name>
<name><surname>Schoofs</surname><given-names>H.M.</given-names></name>
<name><surname>Terras</surname><given-names>F.R.</given-names></name>
<name><surname>Thevissen</surname><given-names>K.</given-names></name>
<name><surname>Osborn</surname><given-names>R.W.</given-names></name>
<name><surname>Rees</surname><given-names>S.B.</given-names></name>
<name><surname>Broekaert</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Gene-encoded anti-microbial peptides from plants</article-title><source>Ciba. Found. Symp.</source><year>1994</year><volume>186</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1002/9780470514658.ch6</pub-id><?supplied-pmid 7768160?><pub-id pub-id-type="pmid">7768160</pub-id></element-citation></ref><ref id="B5-antibiotics-12-01462"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Medema</surname><given-names>M.H.</given-names></name>
<name><surname>Kottmann</surname><given-names>R.</given-names></name>
<name><surname>Yilmaz</surname><given-names>P.</given-names></name>
<name><surname>Cummings</surname><given-names>M.</given-names></name>
<name><surname>Biggins</surname><given-names>J.B.</given-names></name>
<name><surname>Blin</surname><given-names>K.</given-names></name>
<name><surname>de Bruijn</surname><given-names>I.</given-names></name>
<name><surname>Chooi</surname><given-names>Y.H.</given-names></name>
<name><surname>Claesen</surname><given-names>J.</given-names></name>
<name><surname>Coates</surname><given-names>R.C.</given-names></name>
<etal/>
</person-group><article-title>Minimum Information about a Biosynthetic Gene cluster</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1890</pub-id><?supplied-pmid 26284661?><pub-id pub-id-type="pmid">26284661</pub-id></element-citation></ref><ref id="B6-antibiotics-12-01462"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Vellai</surname><given-names>T.</given-names></name>
<name><surname>Hess</surname><given-names>C.</given-names></name>
<name><surname>Makrai</surname><given-names>L.</given-names></name>
<name><surname>Dublecz</surname><given-names>K.</given-names></name>
<name><surname>P&#x000e1;l</surname><given-names>L.</given-names></name>
<name><surname>Moln&#x000e1;r</surname><given-names>A.</given-names></name>
<name><surname>Klein</surname><given-names>M.G.</given-names></name>
<name><surname>Tarasco</surname><given-names>E.</given-names></name>
<name><surname>J&#x000f3;zsa</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>XENOFOOD&#x02014;An Autoclaved Feed Supplement Containing Autoclavable Anti-microbial Peptides&#x02014;Exerts Anticoccidial GI Activity, and Causes Bursa Enlargement, but Has No Detectable Harmful Effects in Broiler Cockerels despite In Vitro Detectable Cytotoxicity on LHM Cells</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>458</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12030458</pub-id><pub-id pub-id-type="pmid">36986380</pub-id></element-citation></ref><ref id="B7-antibiotics-12-01462"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>K.</given-names></name>
<name><surname>Sharma</surname><given-names>K.K.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Jain</surname><given-names>R.</given-names></name>
</person-group><article-title>Peptide-based drug discovery: Current status and recent advances</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>103464</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2022.103464</pub-id><pub-id pub-id-type="pmid">36481586</pub-id></element-citation></ref><ref id="B8-antibiotics-12-01462"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zasloff</surname><given-names>M.</given-names></name>
</person-group><article-title>Anti-microbial Peptides of Multicellular Organisms: My Perspective</article-title><source>Adv. Exp. Med. Biol.</source><year>2019</year><volume>1117</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/978-981-13-3588-4_1</pub-id><pub-id pub-id-type="pmid">30980349</pub-id></element-citation></ref><ref id="B9-antibiotics-12-01462"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boman</surname><given-names>H.G.</given-names></name>
<name><surname>Steiner</surname><given-names>H.</given-names></name>
</person-group><article-title>Humoral immunity in <italic toggle="yes">Cecropia pupae</italic></article-title><source>Curr. Top. Microbiol. Immunol.</source><year>1981</year><volume>94&#x02013;95</volume><fpage>75</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-68120-2_2</pub-id></element-citation></ref><ref id="B10-antibiotics-12-01462"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selsted</surname><given-names>M.E.</given-names></name>
<name><surname>Harwig</surname><given-names>S.S.</given-names></name>
<name><surname>Ganz</surname><given-names>T.</given-names></name>
<name><surname>Schilling</surname><given-names>J.W.</given-names></name>
<name><surname>Lehrer</surname><given-names>R.I.</given-names></name>
</person-group><article-title>Primary structures of three human neutrophil defensins</article-title><source>J. Clin. Investig.</source><year>1985</year><volume>76</volume><fpage>1436</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1172/JCI112121</pub-id><pub-id pub-id-type="pmid">4056036</pub-id></element-citation></ref><ref id="B11-antibiotics-12-01462"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solanki</surname><given-names>S.S.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Kashyap</surname><given-names>P.</given-names></name>
<name><surname>Sansi</surname><given-names>M.S.</given-names></name>
<name><surname>Ali</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Promising role of defensins peptides as therapeutics to combat against viral infection</article-title><source>Microb. Pathog.</source><year>2021</year><volume>155</volume><fpage>104930</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2021.104930</pub-id><?supplied-pmid 33933603?><pub-id pub-id-type="pmid">33933603</pub-id></element-citation></ref><ref id="B12-antibiotics-12-01462"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zasloff</surname><given-names>M.</given-names></name>
</person-group><article-title>Magainins, a class of anti-microbial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1987</year><volume>84</volume><fpage>5449</fpage><lpage>5453</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.15.5449</pub-id><?supplied-pmid 3299384?><pub-id pub-id-type="pmid">3299384</pub-id></element-citation></ref><ref id="B13-antibiotics-12-01462"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Welch</surname><given-names>N.G.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Hossain</surname><given-names>M.A.</given-names></name>
<name><surname>Separovic</surname><given-names>F.</given-names></name>
<name><surname>O&#x02019;Brien-Simpson</surname><given-names>N.M.</given-names></name>
<name><surname>Wade</surname><given-names>J.D.</given-names></name>
</person-group><article-title>(Re)Defining the Proline-Rich Anti-microbial Peptide Family and the Identification of Putative New Members</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><fpage>607769</fpage><pub-id pub-id-type="doi">10.3389/fchem.2020.607769</pub-id><pub-id pub-id-type="pmid">33335890</pub-id></element-citation></ref><ref id="B14-antibiotics-12-01462"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mangano</surname><given-names>K.</given-names></name>
<name><surname>Klepacki</surname><given-names>D.</given-names></name>
<name><surname>Ohanmu</surname><given-names>I.</given-names></name>
<name><surname>Baliga</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Brakel</surname><given-names>A.</given-names></name>
<name><surname>Krizsan</surname><given-names>A.</given-names></name>
<name><surname>Polikanov</surname><given-names>Y.S.</given-names></name>
<name><surname>Hoffmann</surname><given-names>R.</given-names></name>
<name><surname>V&#x000e1;zquez-Laslop</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Inhibition of translation termination by the anti-microbial peptide Drosocin</article-title><source>Nat. Chem. Biol.</source><year>2023</year><volume>19</volume><fpage>1082</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1038/s41589-023-01300-x</pub-id><pub-id pub-id-type="pmid">36997647</pub-id></element-citation></ref><ref id="B15-antibiotics-12-01462"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mojsoska</surname><given-names>B.</given-names></name>
<name><surname>Jenssen</surname><given-names>H.</given-names></name>
</person-group><article-title>Peptides and Peptidomimetics for Anti-microbial Drug Design</article-title><source>Pharmaceuticals</source><year>2015</year><volume>8</volume><fpage>366</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.3390/ph8030366</pub-id><?supplied-pmid 26184232?><pub-id pub-id-type="pmid">26184232</pub-id></element-citation></ref><ref id="B16-antibiotics-12-01462"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sierra</surname><given-names>J.M.</given-names></name>
<name><surname>Fust&#x000e9;</surname><given-names>E.</given-names></name>
<name><surname>Rabanal</surname><given-names>F.</given-names></name>
<name><surname>Vinuesa</surname><given-names>T.</given-names></name>
<name><surname>Vi&#x000f1;as</surname><given-names>M.</given-names></name>
</person-group><article-title>An overview of anti-microbial peptides and the latest advances in their development</article-title><source>Expert Opin. Biol. Ther.</source><year>2017</year><volume>17</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1080/14712598.2017.1315402</pub-id><?supplied-pmid 28368216?><pub-id pub-id-type="pmid">28368216</pub-id></element-citation></ref><ref id="B17-antibiotics-12-01462"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>M.</given-names></name>
<name><surname>Fang</surname><given-names>Z.</given-names></name>
<name><surname>Ren</surname><given-names>W.</given-names></name>
<name><surname>Jiao</surname><given-names>H.</given-names></name>
</person-group><article-title>The Modification and Design of Anti-microbial Peptide</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>904</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.2174/1381612824666180213130318</pub-id><?supplied-pmid 29436993?><pub-id pub-id-type="pmid">29436993</pub-id></element-citation></ref><ref id="B18-antibiotics-12-01462"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romero</surname><given-names>S.M.</given-names></name>
<name><surname>Cardillo</surname><given-names>A.B.</given-names></name>
<name><surname>Mart&#x000ed;nez Ceron</surname><given-names>M.C.</given-names></name>
<name><surname>Camperi</surname><given-names>S.A.</given-names></name>
<name><surname>Giudicessi</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Temporins: An Approach of Potential Pharmaceutic Candidates</article-title><source>Surg. Infect.</source><year>2020</year><volume>21</volume><fpage>309</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1089/sur.2019.266</pub-id></element-citation></ref><ref id="B19-antibiotics-12-01462"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Separovic</surname><given-names>F.</given-names></name>
<name><surname>O&#x02019;Brien-Simpson</surname><given-names>N.M.</given-names></name>
<name><surname>Wade</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Chemically modified and conjugated anti-microbial peptides against superbugs</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>4932</fpage><lpage>4973</lpage><pub-id pub-id-type="doi">10.1039/D0CS01026J</pub-id><?supplied-pmid 33710195?><pub-id pub-id-type="pmid">33710195</pub-id></element-citation></ref><ref id="B20-antibiotics-12-01462"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaoulitch</surname><given-names>S.P.</given-names></name>
</person-group><article-title><italic toggle="yes">Leishmania donovani</italic> Laveran et Mesnil, 1903 parasite auss&#x000e4; les &#x000e9;rythrocytes [<italic toggle="yes">Leishmania donovani</italic> Laveran and Mesnil 1903 also parasitic in erythrocytes]</article-title><source>Bull. Soc. Pathol. Exot. Fil.</source><year>1954</year><volume>47</volume><fpage>244</fpage><lpage>246</lpage></element-citation></ref><ref id="B21-antibiotics-12-01462"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dutra-R&#x000ea;go</surname><given-names>F.</given-names></name>
<name><surname>Freire</surname><given-names>M.L.</given-names></name>
<name><surname>Carvalho</surname><given-names>G.M.L.</given-names></name>
<name><surname>Andrade-Filho</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Revisiting the cave-dwelling sand flies (Diptera, Psychodidae, Phlebotominae) from Brazil: Diversity and potential role in the transmission of <italic toggle="yes">Leishmania</italic> Ross, 1903 (Kinetoplastida: Trypanosomatidae)</article-title><source>Med. Vet.-Entomol.</source><year>2022</year><volume>36</volume><fpage>408</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1111/mve.12578</pub-id><?supplied-pmid 35582971?><pub-id pub-id-type="pmid">35582971</pub-id></element-citation></ref><ref id="B22-antibiotics-12-01462"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDougald</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Blackhead disease (Histomoniasis) in poultry: A critical review</article-title><source>Avian Dis.</source><year>2005</year><volume>49</volume><fpage>462</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1637/7420-081005R.1</pub-id><pub-id pub-id-type="pmid">16404985</pub-id></element-citation></ref><ref id="B23-antibiotics-12-01462"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDougald</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Intestinal protozoa important to poultry</article-title><source>Poult. Sci.</source><year>1998</year><volume>77</volume><fpage>1156</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1093/ps/77.8.1156</pub-id><?supplied-pmid 9706082?><pub-id pub-id-type="pmid">9706082</pub-id></element-citation></ref><ref id="B24-antibiotics-12-01462"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Ganas</surname><given-names>P.</given-names></name>
</person-group><article-title>Histomonas meleagridis&#x02014;New insights into an old pathogen</article-title><source>Vet.-Parasitol.</source><year>2015</year><volume>208</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2014.12.018</pub-id><?supplied-pmid 25576442?><pub-id pub-id-type="pmid">25576442</pub-id></element-citation></ref><ref id="B25-antibiotics-12-01462"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>S.W.</given-names></name>
<name><surname>Sachs</surname><given-names>C.C.</given-names></name>
<name><surname>Kegler</surname><given-names>C.</given-names></name>
<name><surname>Nollmann</surname><given-names>F.I.</given-names></name>
<name><surname>Karas</surname><given-names>M.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Neutral loss fragmentation pattern based screening for arginine-rich natural products in <italic toggle="yes">Xenorhabdus</italic> and <italic toggle="yes">Photorhabdus</italic></article-title><source>Anal. Chem.</source><year>2012</year><volume>84</volume><fpage>6948</fpage><lpage>6955</lpage><pub-id pub-id-type="doi">10.1021/ac300372p</pub-id><?supplied-pmid 22873683?><pub-id pub-id-type="pmid">22873683</pub-id></element-citation></ref><ref id="B26-antibiotics-12-01462"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>S.W.</given-names></name>
<name><surname>Grundmann</surname><given-names>F.</given-names></name>
<name><surname>Kurz</surname><given-names>M.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Fabclavines: Bioactive peptide-polyketide-polyamino hybrids from <italic toggle="yes">Xenorhabdus</italic></article-title><source>ChemBioChem</source><year>2014</year><volume>15</volume><fpage>512</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300802</pub-id><pub-id pub-id-type="pmid">24532262</pub-id></element-citation></ref><ref id="B27-antibiotics-12-01462"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.-M.</given-names></name>
<name><surname>Brachmann</surname><given-names>A.O.</given-names></name>
<name><surname>Westphalen</surname><given-names>M.A.</given-names></name>
<name><surname>Neubacher</surname><given-names>N.</given-names></name>
<name><surname>Tobias</surname><given-names>N.J.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Dual phenazine gene clusters enable diversification during biosynthesis</article-title><source>Nat. Chem. Biol.</source><year>2019</year><volume>15</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0246-1</pub-id><pub-id pub-id-type="pmid">30886436</pub-id></element-citation></ref><ref id="B28-antibiotics-12-01462"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lengyel</surname><given-names>K.</given-names></name>
<name><surname>Lang</surname><given-names>E.</given-names></name>
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Sz&#x000e1;ll&#x000e1;s</surname><given-names>E.</given-names></name>
<name><surname>Schumann</surname><given-names>P.</given-names></name>
<name><surname>Stackebrandt</surname><given-names>E.</given-names></name>
</person-group><article-title>Description of four novel species of <italic toggle="yes">Xenorhabdus</italic>, family Enterobacteriaceae: <italic toggle="yes">Xenorhabdus budapestensis</italic> sp. nov., <italic toggle="yes">Xenorhabdus ehlersii</italic> sp. nov., <italic toggle="yes">Xenorhabdus innexi</italic> sp. nov., and <italic toggle="yes">Xenorhabdus szentirmaii</italic> sp. nov</article-title><source>Syst. Appl. Microbiol.</source><year>2005</year><volume>28</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.syapm.2004.10.004</pub-id><comment>Erratum in <italic toggle="yes">Syst. Appl. Microbiol.</italic>
<bold>2007</bold>, <italic toggle="yes">30</italic>, 83</comment><pub-id pub-id-type="pmid">15830803</pub-id></element-citation></ref><ref id="B29-antibiotics-12-01462"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Gualtieri</surname><given-names>M.</given-names></name>
<name><surname>Zeller</surname><given-names>M.</given-names></name>
<name><surname>Tarasco</surname><given-names>E.</given-names></name>
<name><surname>Klein</surname><given-names>M.G.</given-names></name>
<name><surname>Fodor</surname><given-names>A.M.</given-names></name>
<name><surname>Haynes</surname><given-names>L.</given-names></name>
<name><surname>Lengyel</surname><given-names>K.</given-names></name>
<name><surname>Forst</surname><given-names>S.A.</given-names></name>
<name><surname>Furgani</surname><given-names>G.M.</given-names></name>
<etal/>
</person-group><article-title>Type Strains of Entomopathogenic&#x02013;nematode-Symbiotic Bacterium Species, <italic toggle="yes">Xenorhabdus szentirmaii</italic> (EMC) and <italic toggle="yes">X. budapestensis</italic> (EMA), Are Exceptional Sources of Non-Ribosomal Templated, Large-Target-Spectral, Thermotolerant-Anti-microbial Peptides (by Both), and Iodinin (by EMC)</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>342</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11030342</pub-id><pub-id pub-id-type="pmid">35335666</pub-id></element-citation></ref><ref id="B30-antibiotics-12-01462"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akhurst</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Antibiotic Activity of <italic toggle="yes">Xenorhabdus</italic> spp., Bacteria symbiotically associated with insect pathogenic nematodes of the families Heterorhabditidae and Steinernematidae</article-title><source>J. Gen. Microbiol.</source><year>1982</year><volume>128</volume><fpage>3061</fpage><lpage>3065</lpage><pub-id pub-id-type="doi">10.1099/00221287-128-12-3061</pub-id><pub-id pub-id-type="pmid">7183749</pub-id></element-citation></ref><ref id="B31-antibiotics-12-01462"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogier</surname><given-names>J.-C.</given-names></name>
<name><surname>Pag&#x000e8;s</surname><given-names>S.</given-names></name>
<name><surname>Frayssinet</surname><given-names>M.</given-names></name>
<name><surname>Gaudriault</surname><given-names>S.</given-names></name>
</person-group><article-title>Entomopathogenic&#x02013;nematode-associated microbiota: From monoxenic paradigm to pathobiome</article-title><source>Microbiome</source><year>2020</year><volume>8</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-020-00800-5</pub-id><?supplied-pmid 32093774?><pub-id pub-id-type="pmid">32093774</pub-id></element-citation></ref><ref id="B32-antibiotics-12-01462"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furgani</surname><given-names>G.</given-names></name>
<name><surname>B&#x000f6;sz&#x000f6;rm&#x000e9;nyi</surname><given-names>E.</given-names></name>
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>M&#x000e1;th&#x000e9;-Fodor</surname><given-names>A.</given-names></name>
<name><surname>Forst</surname><given-names>S.</given-names></name>
<name><surname>Hogan</surname><given-names>J.S.</given-names></name>
<name><surname>Katona</surname><given-names>Z.</given-names></name>
<name><surname>Klein</surname><given-names>M.G.</given-names></name>
<name><surname>Stackebrandt</surname><given-names>E.</given-names></name>
<name><surname>Szentirmai</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Xenorhabdus antibiotics: A comparative analysis and potential utility for controlling mastitis caused by bacteria</article-title><source>J. Appl. Microbiol.</source><year>2008</year><volume>104</volume><fpage>745</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2007.03613.x</pub-id><?supplied-pmid 17976177?><pub-id pub-id-type="pmid">17976177</pub-id></element-citation></ref><ref id="B33-antibiotics-12-01462"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Makrai</surname><given-names>L.</given-names></name>
<name><surname>Fodor</surname><given-names>L.</given-names></name>
<name><surname>Venekei</surname><given-names>I.</given-names></name>
<name><surname>Husv&#x000e9;th</surname><given-names>F.</given-names></name>
<name><surname>P&#x000e1;l</surname><given-names>L.</given-names></name>
<name><surname>Moln&#x000e1;r</surname><given-names>A.</given-names></name>
<name><surname>Dublecz</surname><given-names>K.</given-names></name>
<name><surname>Pint&#x000e9;r</surname><given-names>C.</given-names></name>
<name><surname>J&#x000f3;zsa</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Anti-Coccidiosis Potential of Autoclaveable Anti-microbial Peptides from <italic toggle="yes">Xenorhabdus budapestensis</italic> Resistant to Proteolytic (Pepsin, Trypsin) Digestion Based on In Vitro Studies</article-title><source>Microbiol. Res. J. Int.</source><year>2018</year><volume>22</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.9734/MRJI/2017/38516</pub-id></element-citation></ref><ref id="B34-antibiotics-12-01462"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000f6;sz&#x000f6;rm&#x000e9;nyi</surname><given-names>E.</given-names></name>
<name><surname>&#x000c9;rsek</surname><given-names>T.</given-names></name>
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Fodor</surname><given-names>A.M.</given-names></name>
<name><surname>F&#x000f6;ldes</surname><given-names>L.</given-names></name>
<name><surname>Hevesi</surname><given-names>M.</given-names></name>
<name><surname>Hogan</surname><given-names>J.</given-names></name>
<name><surname>Katona</surname><given-names>Z.</given-names></name>
<name><surname>Klein</surname><given-names>M.</given-names></name>
<name><surname>Korm&#x000e1;ny</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Isolation and activity of <italic toggle="yes">Xenorhabdus</italic> anti-microbial compounds against the plant pathogens <italic toggle="yes">Erwinia amylovora</italic> and <italic toggle="yes">Phytophthora nicotianae</italic></article-title><source>J. Appl. Microbiol.</source><year>2009</year><volume>107</volume><fpage>746</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2009.04249.x</pub-id><?supplied-pmid 19320949?><pub-id pub-id-type="pmid">19320949</pub-id></element-citation></ref><ref id="B35-antibiotics-12-01462"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Varga</surname><given-names>I.</given-names></name>
<name><surname>Hevesi</surname><given-names>M.</given-names></name>
<name><surname>M&#x000e1;th&#x000e9;-Fodor</surname><given-names>A.</given-names></name>
<name><surname>Racsko</surname><given-names>J.</given-names></name>
<name><surname>Hogan</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Novel anti-microbial peptides of Xenorhabdus origin against multidrug resistant plant pathogens</article-title><source>A Search for Antibacterial Agents</source><person-group person-group-type="editor">
<name><surname>Bobbarala</surname><given-names>V.</given-names></name>
</person-group><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2012</year><fpage>3</fpage><lpage>32</lpage><comment>Available online: <ext-link xlink:href="https://www.intechopen.com/books/2129" ext-link-type="uri">https://www.intechopen.com/books/2129</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2012-06-30">(accessed on 30 June 2012)</date-in-citation></element-citation></ref><ref id="B36-antibiotics-12-01462"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vozik</surname><given-names>D.</given-names></name>
<name><surname>B&#x000e9;lafi-Bak&#x000f3;</surname><given-names>K.</given-names></name>
<name><surname>Hevesi</surname><given-names>M.</given-names></name>
<name><surname>B&#x000f6;sz&#x000f6;rm&#x000e9;nyi</surname><given-names>E.</given-names></name>
<name><surname>Fodor</surname><given-names>A.</given-names></name>
</person-group><article-title>Effectiveness of a Peptide-rich Fraction from <italic toggle="yes">Xenorhabdus budapestensis</italic> Culture against Fire Blight Disease on Apple Blossoms</article-title><source>Not. Bot. Hortic. Agrobot.</source><year>2015</year><volume>43</volume><fpage>547</fpage><lpage>553</lpage><comment>Available online: <ext-link xlink:href="https://www.notulaebotanicae.ro/ndex.php/index" ext-link-type="uri">https://www.notulaebotanicae.ro/ndex.php/index</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-22">(accessed on 22 February 2022)</date-in-citation><pub-id pub-id-type="doi">10.15835/nbha4329997</pub-id></element-citation></ref><ref id="B37-antibiotics-12-01462"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fern&#x000e1;ndez-Ar&#x000e9;valo</surname><given-names>A.</given-names></name>
<name><surname>El Baidouri</surname><given-names>F.</given-names></name>
<name><surname>Ravel</surname><given-names>C.</given-names></name>
<name><surname>Ballart</surname><given-names>C.</given-names></name>
<name><surname>Abras</surname><given-names>A.</given-names></name>
<name><surname>Lachaud</surname><given-names>L.</given-names></name>
<name><surname>Tebar</surname><given-names>S.</given-names></name>
<name><surname>Lami</surname><given-names>P.</given-names></name>
<name><surname>Pratlong</surname><given-names>F.</given-names></name>
<name><surname>G&#x000e1;llego</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The <italic toggle="yes">Leishmania donovani</italic> species complex: A new insight into taxonomy</article-title><source>Int. J. Parasitol.</source><year>2020</year><volume>50</volume><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2020.06.013</pub-id><pub-id pub-id-type="pmid">32889062</pub-id></element-citation></ref><ref id="B38-antibiotics-12-01462"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGwire</surname><given-names>B.S.</given-names></name>
<name><surname>Satoskar</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Leishmaniasis: Clinical syndromes and treatment</article-title><source>QJM</source><year>2014</year><volume>107</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hct116</pub-id><pub-id pub-id-type="pmid">23744570</pub-id></element-citation></ref><ref id="B39-antibiotics-12-01462"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alvar</surname><given-names>J.</given-names></name>
<name><surname>Ca&#x000f1;avate</surname><given-names>C.</given-names></name>
<name><surname>Molina</surname><given-names>R.</given-names></name>
<name><surname>Moreno</surname><given-names>J.</given-names></name>
<name><surname>Nieto</surname><given-names>J.</given-names></name>
</person-group><article-title>Canine leishmaniasis</article-title><source>Adv. Parasitol.</source><year>2004</year><volume>57</volume><fpage>1</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/s0065-308x(04)57001-x</pub-id><pub-id pub-id-type="pmid">15504537</pub-id></element-citation></ref><ref id="B40-antibiotics-12-01462"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dantas-Torres</surname><given-names>F.</given-names></name>
<name><surname>Mir&#x000f3;</surname><given-names>G.</given-names></name>
<name><surname>Baneth</surname><given-names>G.</given-names></name>
<name><surname>Bourdeau</surname><given-names>P.</given-names></name>
<name><surname>Breitschwerdt</surname><given-names>E.</given-names></name>
<name><surname>Capelli</surname><given-names>G.</given-names></name>
<name><surname>Cardoso</surname><given-names>L.</given-names></name>
<name><surname>Day</surname><given-names>M.J.</given-names></name>
<name><surname>Dobler</surname><given-names>G.</given-names></name>
<name><surname>Ferrer</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Canine Leishmaniasis Control in the Context of One Health</article-title><source>Emerg. Infect. Dis.</source><year>2019</year><volume>25</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3201/eid2512.190164</pub-id></element-citation></ref><ref id="B41-antibiotics-12-01462"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>D.M.</given-names></name>
<name><surname>Oghumu</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>G.</given-names></name>
<name><surname>McGwire</surname><given-names>B.S.</given-names></name>
<name><surname>Drew</surname><given-names>M.E.</given-names></name>
<name><surname>Satoskar</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Mechanisms of cellular invasion by intracellular parasites</article-title><source>Cell Mol. Life Sci.</source><year>2014</year><volume>71</volume><fpage>1245</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1491-1</pub-id><pub-id pub-id-type="pmid">24221133</pub-id></element-citation></ref><ref id="B42-antibiotics-12-01462"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burza</surname><given-names>S.</given-names></name>
<name><surname>Croft</surname><given-names>S.L.</given-names></name>
<name><surname>Boelaert</surname><given-names>M.</given-names></name>
</person-group><article-title>Leishmaniasis</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>951</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31204-2</pub-id><pub-id pub-id-type="pmid">30126638</pub-id></element-citation></ref><ref id="B43-antibiotics-12-01462"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Safavi</surname><given-names>M.</given-names></name>
<name><surname>Eshaghi</surname><given-names>H.</given-names></name>
<name><surname>Hajihassani</surname><given-names>Z.</given-names></name>
</person-group><article-title>Visceral Leishmaniasis: Kala-azar</article-title><source>Diagn. Cytopathol.</source><year>2021</year><volume>49</volume><fpage>446</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1002/dc.24671</pub-id><?supplied-pmid 33225605?><pub-id pub-id-type="pmid">33225605</pub-id></element-citation></ref><ref id="B44-antibiotics-12-01462"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Altamura</surname><given-names>F.</given-names></name>
<name><surname>Rajesh</surname><given-names>R.</given-names></name>
<name><surname>Catta-Preta</surname><given-names>C.M.C.</given-names></name>
<name><surname>Moretti</surname><given-names>N.S.</given-names></name>
<name><surname>Cestari</surname><given-names>I.</given-names></name>
</person-group><article-title>The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets</article-title><source>Drug Dev. Res.</source><year>2022</year><volume>83</volume><fpage>225</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1002/ddr.21664</pub-id><?supplied-pmid 32249457?><pub-id pub-id-type="pmid">32249457</pub-id></element-citation></ref><ref id="B45-antibiotics-12-01462"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mauel</surname><given-names>J.</given-names></name>
</person-group><article-title>Vaccination Against Leishmania Infections</article-title><source>Curr. Drug Targets-Immune Endocr. Metab. Disord.</source><year>2002</year><volume>2</volume><fpage>201</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.2174/1568008023340631</pub-id></element-citation></ref><ref id="B46-antibiotics-12-01462"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibarra-Meneses</surname><given-names>A.V.</given-names></name>
<name><surname>Corbeil</surname><given-names>A.</given-names></name>
<name><surname>Wagner</surname><given-names>V.</given-names></name>
<name><surname>Beaudry</surname><given-names>F.</given-names></name>
<name><surname>Monte-Neto</surname><given-names>R.L.D.</given-names></name>
<name><surname>Fernandez-Prada</surname><given-names>C.</given-names></name>
</person-group><article-title>Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>954144</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.954144</pub-id><pub-id pub-id-type="pmid">35992178</pub-id></element-citation></ref><ref id="B47-antibiotics-12-01462"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Douanne</surname><given-names>N.</given-names></name>
<name><surname>Wagner</surname><given-names>V.</given-names></name>
<name><surname>Roy</surname><given-names>G.</given-names></name>
<name><surname>Leprohon</surname><given-names>P.</given-names></name>
<name><surname>Ouellette</surname><given-names>M.</given-names></name>
<name><surname>Fernandez-Prada</surname><given-names>C.</given-names></name>
</person-group><article-title>MRPA-independent mechanisms of antimony resistance in Leishmania infantum</article-title><source>Int. J. Parasitol. Drugs Drug Resist.</source><year>2020</year><volume>13</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2020.03.003</pub-id><?supplied-pmid 32413766?><pub-id pub-id-type="pmid">32413766</pub-id></element-citation></ref><ref id="B48-antibiotics-12-01462"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golenser</surname><given-names>J.</given-names></name>
<name><surname>Domb</surname><given-names>A.</given-names></name>
</person-group><article-title>New formulations and derivatives of Amphotericin B for treatment of leishmaniasis</article-title><source>Mini-Rev. Med. Chem.</source><year>2006</year><volume>6</volume><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.2174/138955706775476037</pub-id><pub-id pub-id-type="pmid">16472184</pub-id></element-citation></ref><ref id="B49-antibiotics-12-01462"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lollis</surname><given-names>L.</given-names></name>
<name><surname>Gerhold</surname><given-names>R.</given-names></name>
<name><surname>McDougald</surname><given-names>L.</given-names></name>
<name><surname>Beckstead</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular Characterization of <italic toggle="yes">Histomonas meleagridis</italic> and Other Parabasalids in the United States Using the 5.8S, ITS-1, and ITS-2 rRNA Regions</article-title><source>J. Parasitol.</source><year>2011</year><volume>97</volume><fpage>610</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1645/GE-2648.1</pub-id><pub-id pub-id-type="pmid">21506848</pub-id></element-citation></ref><ref id="B50-antibiotics-12-01462"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmieri</surname><given-names>N.</given-names></name>
<name><surname>de Jesus Ramires</surname><given-names>M.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
</person-group><article-title>Complete genomes of the eukaryotic poultry parasite <italic toggle="yes">Histomonas meleagridis</italic>: Linking sequence analysis with virulence/attenuation</article-title><source>BMC Genom.</source><year>2021</year><volume>22</volume><elocation-id>753</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-021-08059-2</pub-id></element-citation></ref><ref id="B51-antibiotics-12-01462"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beer</surname><given-names>L.C.</given-names></name>
<name><surname>Petrone-Garcia</surname><given-names>V.M.</given-names></name>
<name><surname>Graham</surname><given-names>B.D.</given-names></name>
<name><surname>Hargis</surname><given-names>B.M.</given-names></name>
<name><surname>Tellez-Isaias</surname><given-names>G.</given-names></name>
<name><surname>Vuong</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Histomonosis in Poultry: A Comprehensive Review</article-title><source>Front. Vet.-Sci.</source><year>2022</year><volume>9</volume><fpage>880738</fpage><pub-id pub-id-type="doi">10.3389/fvets.2022.880738</pub-id><pub-id pub-id-type="pmid">35601402</pub-id></element-citation></ref><ref id="B52-antibiotics-12-01462"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganas</surname><given-names>P.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Gl&#x000f6;smann</surname><given-names>M.</given-names></name>
<name><surname>Hess</surname><given-names>C.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Escherichia coli</italic> strongly supports the growth of <italic toggle="yes">Histomonas meleagridis</italic>, in a monoxenic culture, without influence on its pathogenicity</article-title><source>Int. J. Parasitol.</source><year>2012</year><volume>42</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2012.07.007</pub-id><?supplied-pmid 22921600?><pub-id pub-id-type="pmid">22921600</pub-id></element-citation></ref><ref id="B53-antibiotics-12-01462"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitra</surname><given-names>T.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
</person-group><article-title>The 60S ribosomal protein L13 is the most preferable reference gene to investigate gene expression in selected organs from turkeys and chickens, in context of different infection models</article-title><source>Vet.-Res.</source><year>2016</year><volume>47</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s13567-016-0388-z</pub-id><?supplied-pmid 27765062?><pub-id pub-id-type="pmid">27765062</pub-id></element-citation></ref><ref id="B54-antibiotics-12-01462"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kidane</surname><given-names>F.A.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Mitra</surname><given-names>T.</given-names></name>
<name><surname>Wernsdorf</surname><given-names>P.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
</person-group><article-title>In situ hybridization to detect and localize signature cytokines of T-helper (Th) 1 and Th2 immune responses in chicken tissues</article-title><source>Vet.-Immunol. Immunopathol.</source><year>2016</year><volume>175</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2016.05.007</pub-id><pub-id pub-id-type="pmid">27269792</pub-id></element-citation></ref><ref id="B55-antibiotics-12-01462"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitra</surname><given-names>T.</given-names></name>
<name><surname>Kidane</surname><given-names>F.A.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
</person-group><article-title>Unravelling the Immunity of Poultry Against the Extracellular Protozoan Parasite <italic toggle="yes">Histomonas meleagridis</italic> Is a Cornerstone for Vaccine Development: A Review</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2518</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02518</pub-id><pub-id pub-id-type="pmid">30450097</pub-id></element-citation></ref><ref id="B56-antibiotics-12-01462"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Ganas</surname><given-names>P.</given-names></name>
<name><surname>Sulejmanovic</surname><given-names>T.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Histomonosis in poultry: Previous and current strategies for prevention and therapy</article-title><source>Avian Pathol.</source><year>2017</year><volume>46</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/03079457.2016.1229458</pub-id><?supplied-pmid 27624771?><pub-id pub-id-type="pmid">27624771</pub-id></element-citation></ref><ref id="B57-antibiotics-12-01462"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hauck</surname><given-names>R.</given-names></name>
<name><surname>Balczulat</surname><given-names>S.</given-names></name>
<name><surname>Hafez</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Detection of DNA of <italic toggle="yes">Histomonas meleagridis</italic> and <italic toggle="yes">Tetratrichomonas gallinarum</italic> in German poultry flocks between 2004 and 2008</article-title><source>Avian Dis.</source><year>2010</year><volume>54</volume><fpage>1021</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1637/9261-012910-Reg.1</pub-id><pub-id pub-id-type="pmid">20945783</pub-id></element-citation></ref><ref id="B58-antibiotics-12-01462"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lagler</surname><given-names>J.</given-names></name>
<name><surname>Schmidt</surname><given-names>S.</given-names></name>
<name><surname>Mitra</surname><given-names>T.</given-names></name>
<name><surname>Stadler</surname><given-names>M.</given-names></name>
<name><surname>Wernsdorf</surname><given-names>P.</given-names></name>
<name><surname>Grafl</surname><given-names>B.</given-names></name>
<name><surname>Hatfaludi</surname><given-names>T.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
<name><surname>Gerner</surname><given-names>W.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
</person-group><article-title>Comparative investigation of IFN-&#x003b3;-producing T cells in chickens and turkeys following vaccination and infection with the extracellular parasite Histomonas meleagridis</article-title><source>Dev. Comp. Immunol.</source><year>2021</year><volume>116</volume><fpage>103949</fpage><pub-id pub-id-type="doi">10.1016/j.dci.2020.103949</pub-id><pub-id pub-id-type="pmid">33253751</pub-id></element-citation></ref><ref id="B59-antibiotics-12-01462"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gruber</surname><given-names>J.</given-names></name>
<name><surname>Ganas</surname><given-names>P.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Long-term in vitro cultivation of <italic toggle="yes">Histomonas meleagridis</italic> coincides with the dominance of a very distinct phenotype of the parasite exhibiting increased tenacity and improved cell yields</article-title><source>Parasitology</source><year>2017</year><volume>144</volume><fpage>1253</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1017/S0031182017000646</pub-id><pub-id pub-id-type="pmid">28478784</pub-id></element-citation></ref><ref id="B60-antibiotics-12-01462"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Interplay between <italic toggle="yes">Histomonas meleagridis</italic> and Bacteria: Mutualistic or Predator&#x02013;Prey?</article-title><source>Trends Parasitol.</source><year>2020</year><volume>36</volume><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2019.12.015</pub-id><pub-id pub-id-type="pmid">31982329</pub-id></element-citation></ref><ref id="B61-antibiotics-12-01462"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hauck</surname><given-names>R.</given-names></name>
<name><surname>Hafez</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Partial sequence of the beta-tubulin of <italic toggle="yes">Histomonas meleagridis</italic> and the activity of benzimidazoles against <italic toggle="yes">H. meleagridis</italic> in vitro</article-title><source>Parasitol. Res.</source><year>2009</year><volume>104</volume><fpage>1183</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1007/s00436-008-1309-5</pub-id><pub-id pub-id-type="pmid">19101732</pub-id></element-citation></ref><ref id="B62-antibiotics-12-01462"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grabensteiner</surname><given-names>E.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Arshad</surname><given-names>N.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Antiprotozoal activities determined in vitro and in vivo of certain plant extracts against <italic toggle="yes">Histomonas meleagridis</italic>, <italic toggle="yes">Tetratrichomonas gallinarum</italic> and <italic toggle="yes">Blastocystis</italic> sp</article-title><source>Parasitol. Res.</source><year>2008</year><volume>103</volume><fpage>1257</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1007/s00436-008-1122-1</pub-id><pub-id pub-id-type="pmid">18751730</pub-id></element-citation></ref><ref id="B63-antibiotics-12-01462"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>M.</given-names></name>
<name><surname>McDougald</surname><given-names>L.R.</given-names></name>
<name><surname>Beckstead</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Blackhead disease: Reduced sensitivity of <italic toggle="yes">Histomonas meleagridis</italic> to nitarsone in vitro and in vivo</article-title><source>Avian Dis.</source><year>2014</year><volume>58</volume><fpage>60</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1637/10635-080913-Reg.1</pub-id><?supplied-pmid 24758114?><pub-id pub-id-type="pmid">24758114</pub-id></element-citation></ref><ref id="B64-antibiotics-12-01462"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>J.B.</given-names></name>
<name><surname>Jordan</surname><given-names>B.</given-names></name>
<name><surname>Vidyashankar</surname><given-names>A.</given-names></name>
<name><surname>Bishop</surname><given-names>A.</given-names></name>
<name><surname>Kaplan</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Fenbendazole resistance in <italic toggle="yes">Heterakis gallinarum</italic>, the vector of <italic toggle="yes">Histomonas meleagridis</italic>, on a broiler breeder farm in South Carolina</article-title><source>Vet.-Parasitol. Reg. Stud. Rep.</source><year>2022</year><volume>36</volume><fpage>100785</fpage><pub-id pub-id-type="doi">10.1016/j.vprsr.2022.100785</pub-id><?supplied-pmid 36436885?><pub-id pub-id-type="pmid">36436885</pub-id></element-citation></ref><ref id="B65-antibiotics-12-01462"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brioschi</surname><given-names>M.B.</given-names></name>
<name><surname>Coser</surname><given-names>E.M.</given-names></name>
<name><surname>Coelho</surname><given-names>A.C.</given-names></name>
<name><surname>Gadelha</surname><given-names>F.R.</given-names></name>
<name><surname>Miguel</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Models for cytotoxicity screening of antileishmanial drugs: What has been done so far?</article-title><source>Int. J. Antimicrob. Agents</source><year>2022</year><volume>60</volume><fpage>106612</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2022.106612</pub-id><?supplied-pmid 35691601?><pub-id pub-id-type="pmid">35691601</pub-id></element-citation></ref><ref id="B66-antibiotics-12-01462"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tominaga</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Saeki</surname><given-names>H.</given-names></name>
<name><surname>Matsuno</surname><given-names>S.</given-names></name>
<name><surname>Tachibana</surname><given-names>T.</given-names></name>
<name><surname>Kudo</surname><given-names>T.</given-names></name>
</person-group><article-title>Establishment of an activated macrophage cell line, A-THP-1, and its properties</article-title><source>Tohoku J. Exp. Med.</source><year>1998</year><volume>186</volume><fpage>99</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1620/tjem.186.99</pub-id><pub-id pub-id-type="pmid">10223614</pub-id></element-citation></ref><ref id="B67-antibiotics-12-01462"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andreu</surname><given-names>N.</given-names></name>
<name><surname>Phelan</surname><given-names>J.</given-names></name>
<name><surname>de Sessions</surname><given-names>P.F.</given-names></name>
<name><surname>Cliff</surname><given-names>J.M.</given-names></name>
<name><surname>Clark</surname><given-names>T.G.</given-names></name>
<name><surname>Hibberd</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Primary macrophages and J774 cells respond differently to infection with Mycobacterium tuberculosis</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>42225</fpage><pub-id pub-id-type="doi">10.1038/srep42225</pub-id><pub-id pub-id-type="pmid">28176867</pub-id></element-citation></ref><ref id="B68-antibiotics-12-01462"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geroldinger</surname><given-names>G.</given-names></name>
<name><surname>Rezk</surname><given-names>M.</given-names></name>
<name><surname>Idris</surname><given-names>R.</given-names></name>
<name><surname>Gruber</surname><given-names>V.</given-names></name>
<name><surname>Tonner</surname><given-names>M.</given-names></name>
<name><surname>Moldzio</surname><given-names>R.</given-names></name>
<name><surname>Staniek</surname><given-names>K.</given-names></name>
<name><surname>Monzote</surname><given-names>L.</given-names></name>
<name><surname>Gille</surname><given-names>L.</given-names></name>
</person-group><article-title>Techniques to study phagocytosis and uptake of <italic toggle="yes">Leishmania tarentolae</italic> by J774 macrophages</article-title><source>Exp. Parasitol.</source><year>2019</year><volume>197</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2019.01.012</pub-id><pub-id pub-id-type="pmid">30677395</pub-id></element-citation></ref><ref id="B69-antibiotics-12-01462"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawaguchi</surname><given-names>T.</given-names></name>
<name><surname>Nomura</surname><given-names>K.</given-names></name>
<name><surname>Hirayama</surname><given-names>Y.</given-names></name>
<name><surname>Kitagawa</surname><given-names>T.</given-names></name>
</person-group><article-title>Establishment and characterization of a chicken hepatocellular car-cinoma, cell line, LMH</article-title><source>Cancer Res.</source><year>1987</year><volume>47</volume><fpage>4460</fpage><lpage>4464</lpage><pub-id pub-id-type="pmid">3607775</pub-id></element-citation></ref><ref id="B70-antibiotics-12-01462"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>A.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Berger</surname><given-names>E.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Trichomonas gallinae, in comparison to <italic toggle="yes">Tetratrichomonas gallinarum</italic>, induces distinctive cytopathogenic effects in tissue cultures</article-title><source>Vet.-Parasitol.</source><year>2012</year><volume>186</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2011.11.037</pub-id><pub-id pub-id-type="pmid">22172581</pub-id></element-citation></ref><ref id="B71-antibiotics-12-01462"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forst</surname><given-names>S.</given-names></name>
<name><surname>Nealson</surname><given-names>K.</given-names></name>
</person-group><article-title>Molecular biology of the symbiotic-pathogenic bacteria <italic toggle="yes">Xenorhabdus</italic> spp. and <italic toggle="yes">Photorhabdus</italic> spp</article-title><source>Microbiol. Rev.</source><year>1996</year><volume>60</volume><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1128/mr.60.1.21-43.1996</pub-id><pub-id pub-id-type="pmid">8852894</pub-id></element-citation></ref><ref id="B72-antibiotics-12-01462"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akhurst</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Morphological and functional dimorphism in <italic toggle="yes">Xenorhabdus</italic> spp., Bacteria symbiotically associated with the insect pathogenic nematodes Neoaplectana and Heterorhabditis</article-title><source>J. Gen. Microbiol.</source><year>1980</year><volume>121</volume><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1099/00221287-121-2-303</pub-id></element-citation></ref><ref id="B73-antibiotics-12-01462"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boemare</surname><given-names>N.E.</given-names></name>
<name><surname>Akhurst</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Biochemical and physiological characterization of colony form variants in <italic toggle="yes">Xenorhabdus</italic> spp. (Enterobacteriaceae)</article-title><source>Microbiology</source><year>1988</year><volume>134</volume><fpage>751</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1099/00221287-134-3-751</pub-id></element-citation></ref><ref id="B74-antibiotics-12-01462"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joyce</surname><given-names>S.A.</given-names></name>
<name><surname>Clarke</surname><given-names>D.J.</given-names></name>
</person-group><article-title>A hexA homologue from Photorhabdus regulates pathogenicity, symbiosis and phenotypic variation</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>47</volume><fpage>1445</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03389.x</pub-id><?supplied-pmid 12603747?><pub-id pub-id-type="pmid">12603747</pub-id></element-citation></ref><ref id="B75-antibiotics-12-01462"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Langer</surname><given-names>A.</given-names></name>
<name><surname>Moldovan</surname><given-names>A.</given-names></name>
<name><surname>Harmath</surname><given-names>C.</given-names></name>
<name><surname>Joyce</surname><given-names>S.A.</given-names></name>
<name><surname>Clarke</surname><given-names>D.J.</given-names></name>
<name><surname>Heermann</surname><given-names>R.</given-names></name>
</person-group><article-title>HexA is a versatile regulator involved in the control of phenotypic heterogeneity of <italic toggle="yes">Photorhabdus luminescens</italic></article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0176535</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0176535</pub-id><pub-id pub-id-type="pmid">28448559</pub-id></element-citation></ref><ref id="B76-antibiotics-12-01462"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tobias</surname><given-names>N.J.</given-names></name>
<name><surname>Mishra</surname><given-names>B.</given-names></name>
<name><surname>Gupta</surname><given-names>D.K.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Thines</surname><given-names>M.</given-names></name>
<name><surname>Stinear</surname><given-names>T.P.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Genome comparisons provide insights into the role of secondary metabolites in the pathogenic phase of the Photorhabdus life cycle</article-title><source>BMC Genom.</source><year>2016</year><volume>17</volume><elocation-id>537</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-016-2862-4</pub-id></element-citation></ref><ref id="B77-antibiotics-12-01462"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tobias</surname><given-names>N.J.</given-names></name>
<name><surname>Heinrich</surname><given-names>A.K.</given-names></name>
<name><surname>Eresmann</surname><given-names>H.</given-names></name>
<name><surname>Wright</surname><given-names>P.R.</given-names></name>
<name><surname>Neubacher</surname><given-names>N.</given-names></name>
<name><surname>Backofen</surname><given-names>R.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Photorhabdus-nematode symbiosis is dependent on hfq-mediated regulation of secondary metabolites</article-title><source>Environ. Microbiol.</source><year>2017</year><volume>19</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.13502</pub-id><pub-id pub-id-type="pmid">27555343</pub-id></element-citation></ref><ref id="B78-antibiotics-12-01462"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neubacher</surname><given-names>N.</given-names></name>
<name><surname>Tobias</surname><given-names>N.J.</given-names></name>
<name><surname>Huber</surname><given-names>M.</given-names></name>
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Glatter</surname><given-names>T.</given-names></name>
<name><surname>Pidot</surname><given-names>S.J.</given-names></name>
<name><surname>Stinear</surname><given-names>T.P.</given-names></name>
<name><surname>L&#x000fc;tticke</surname><given-names>A.L.</given-names></name>
<name><surname>Papenfort</surname><given-names>K.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Symbiosis, virulence and natural-product biosynthesis in entomopathogenic bacteria are regulated by a small RNA</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1481</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00797-5</pub-id><pub-id pub-id-type="pmid">33139881</pub-id></element-citation></ref><ref id="B79-antibiotics-12-01462"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bode</surname><given-names>E.</given-names></name>
<name><surname>Heinrich</surname><given-names>A.K.</given-names></name>
<name><surname>Hirschmann</surname><given-names>M.</given-names></name>
<name><surname>Abebew</surname><given-names>D.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Vo</surname><given-names>T.D.</given-names></name>
<name><surname>Wesche</surname><given-names>F.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Gr&#x000fc;n</surname><given-names>P.</given-names></name>
<name><surname>Simonyi</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Promoter Activation in &#x00394;<italic toggle="yes">hfq</italic> Mutants as an Efficient Tool for Specialized Metabolite Production Enabling Direct Bioactivity Testing</article-title><source>Angew. Chem. Int. Ed.</source><year>2019</year><volume>58</volume><fpage>18957</fpage><lpage>18963</lpage><pub-id pub-id-type="doi">10.1002/anie.201910563</pub-id></element-citation></ref><ref id="B80-antibiotics-12-01462"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wenski</surname><given-names>S.L.</given-names></name>
<name><surname>Kolbert</surname><given-names>D.</given-names></name>
<name><surname>Grammbitter</surname><given-names>G.L.C.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Fabclavine biosynthesis in <italic toggle="yes">X. szentirmaii</italic>: Shortened derivatives and characterization of the thioester reductase FclG and the condensation domain-like protein FclL</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2019</year><volume>46</volume><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1007/s10295-018-02124-8</pub-id><pub-id pub-id-type="pmid">30610410</pub-id></element-citation></ref><ref id="B81-antibiotics-12-01462"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wenski</surname><given-names>S.L.</given-names></name>
<name><surname>Cimen</surname><given-names>H.</given-names></name>
<name><surname>Berghaus</surname><given-names>N.</given-names></name>
<name><surname>Fuchs</surname><given-names>S.W.</given-names></name>
<name><surname>Hazir</surname><given-names>S.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Fabclavine diversity in <italic toggle="yes">Xenorhabdus</italic> bacteria</article-title><source>Beilstein J. Org. Chem.</source><year>2020</year><volume>16</volume><fpage>956</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.3762/bjoc.16.84</pub-id><pub-id pub-id-type="pmid">32461774</pub-id></element-citation></ref><ref id="B82-antibiotics-12-01462"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cimen</surname><given-names>H.</given-names></name>
<name><surname>Touray</surname><given-names>M.</given-names></name>
<name><surname>Gulsen</surname><given-names>S.H.</given-names></name>
<name><surname>Hazir</surname><given-names>S.</given-names></name>
</person-group><article-title>Natural products from Photorhabdus and Xenorhabdus: Mechanisms and impacts</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2022</year><volume>106</volume><fpage>4387</fpage><lpage>4399</lpage><pub-id pub-id-type="doi">10.1007/s00253-022-12023-9</pub-id><pub-id pub-id-type="pmid">35723692</pub-id></element-citation></ref><ref id="B83-antibiotics-12-01462"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gulsen</surname><given-names>S.H.</given-names></name>
<name><surname>Tileklioglu</surname><given-names>E.</given-names></name>
<name><surname>Bode</surname><given-names>E.</given-names></name>
<name><surname>Cimen</surname><given-names>H.</given-names></name>
<name><surname>Ertabaklar</surname><given-names>H.</given-names></name>
<name><surname>Ulug</surname><given-names>D.</given-names></name>
<name><surname>Ertug</surname><given-names>S.</given-names></name>
<name><surname>Wenski</surname><given-names>S.L.</given-names></name>
<name><surname>Touray</surname><given-names>M.</given-names></name>
<name><surname>Hazir</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Antiprotozoal activity of different Xenorhabdus and Photorhabdus bacterial secondary metabolites and identification of bioactive compounds using the easyPACId approach</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>10779</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-13722-z</pub-id><?supplied-pmid 35750682?><pub-id pub-id-type="pmid">35750682</pub-id></element-citation></ref><ref id="B84-antibiotics-12-01462"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherepanov</surname><given-names>P.P.</given-names></name>
<name><surname>Wackernagel</surname><given-names>W.</given-names></name>
</person-group><article-title>Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant</article-title><source>Gene</source><year>1995</year><volume>158</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(95)00193-A</pub-id><?supplied-pmid 7789817?><pub-id pub-id-type="pmid">7789817</pub-id></element-citation></ref><ref id="B85-antibiotics-12-01462"><label>85.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Gibson</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Studies on the Epstein-Barr Virus Genome</article-title><source>Ph.D. Thesis</source><publisher-name>University of Cambridge</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>1984</year></element-citation></ref><ref id="B86-antibiotics-12-01462"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simon</surname><given-names>R.</given-names></name>
<name><surname>Priefer</surname><given-names>U.</given-names></name>
<name><surname>P&#x000fc;hler</surname><given-names>A.</given-names></name>
</person-group><article-title>A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria</article-title><source>Bio/Technol.</source><year>1983</year><volume>1</volume><fpage>784</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1038/nbt1183-784</pub-id></element-citation></ref><ref id="B87-antibiotics-12-01462"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Datsenko</surname><given-names>K.A.</given-names></name>
<name><surname>Wanner</surname><given-names>B.L.</given-names></name>
</person-group><article-title>One-step inactivation of chromosomal genes in <italic toggle="yes">Escherichia coli</italic> K-12 using PCR products</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>6640</fpage><lpage>6645</lpage><pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id><?supplied-pmid 10829079?><pub-id pub-id-type="pmid">10829079</pub-id></element-citation></ref><ref id="B88-antibiotics-12-01462"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Xia</surname><given-names>L.</given-names></name>
<name><surname>Ding</surname><given-names>X.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<name><surname>Bian</surname><given-names>X.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
<name><surname>Fu</surname><given-names>J.</given-names></name>
<name><surname>Stewart</surname><given-names>A.F.</given-names></name>
<etal/>
</person-group><article-title>A new recombineering system for Photorhabdus and Xenorhabdus</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>e36</fpage><pub-id pub-id-type="doi">10.1093/nar/gku1336</pub-id><?supplied-pmid 25539914?><pub-id pub-id-type="pmid">25539914</pub-id></element-citation></ref><ref id="B89-antibiotics-12-01462"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Short</surname><given-names>J.M.</given-names></name>
<name><surname>Fernandez</surname><given-names>J.M.</given-names></name>
<name><surname>Sorge</surname><given-names>J.A.</given-names></name>
<name><surname>Huse</surname><given-names>W.D.</given-names></name>
</person-group><article-title>&#x003bb; ZAP: A bacteriophage &#x003bb; expression vector with in vivo excision properties</article-title><source>Nucleic Acids Res.</source><year>1988</year><volume>16</volume><fpage>7583</fpage><lpage>7600</lpage><pub-id pub-id-type="doi">10.1093/nar/16.15.7583</pub-id><pub-id pub-id-type="pmid">2970625</pub-id></element-citation></ref><ref id="B90-antibiotics-12-01462"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000f3;sfai</surname><given-names>G.</given-names></name>
<name><surname>Koob</surname><given-names>M.D.</given-names></name>
<name><surname>Kirkpatrick</surname><given-names>H.A.</given-names></name>
<name><surname>Blattner</surname><given-names>F.R.</given-names></name>
</person-group><article-title>Versatile insertion plasmids for targeted genome manipu-lations in bacteria: Isolation, deletion, and rescue of the pathogenicity island LEE of the Escherichia coli O157:H7 genome</article-title><source>J. Bacteriol.</source><year>1997</year><volume>179</volume><fpage>4426</fpage><lpage>4428</lpage><pub-id pub-id-type="doi">10.1128/jb.179.13.4426-4428.1997</pub-id><?supplied-pmid 9209066?><pub-id pub-id-type="pmid">9209066</pub-id></element-citation></ref><ref id="B91-antibiotics-12-01462"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quandt</surname><given-names>J.</given-names></name>
<name><surname>Hynes</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Versatile suicide vectors which allow direct selection for gene replacement in Gram-negative bacteria</article-title><source>Gene</source><year>1993</year><volume>127</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(93)90611-6</pub-id><?supplied-pmid 8486283?><pub-id pub-id-type="pmid">8486283</pub-id></element-citation></ref><ref id="B92-antibiotics-12-01462"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagy</surname><given-names>I.</given-names></name>
<name><surname>Szab&#x000f3;</surname><given-names>M.</given-names></name>
<name><surname>Hegyi</surname><given-names>A.</given-names></name>
<name><surname>Kiss</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Genomic Island 1 requires a self-encoded small RNA for mobilization</article-title><source>Mol. Microbiol.</source><year>2021</year><volume>116</volume><fpage>1533</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1111/mmi.14846</pub-id><pub-id pub-id-type="pmid">34784078</pub-id></element-citation></ref><ref id="B93-antibiotics-12-01462"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waterfield</surname><given-names>N.</given-names></name>
<name><surname>Kamita</surname><given-names>S.G.</given-names></name>
<name><surname>Hammock</surname><given-names>B.D.</given-names></name>
<name><surname>Ffrench-Constant</surname><given-names>R.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Photorhabdus</italic> Pir toxins are similar to a developmentally regulated insect protein but show no juvenile hormone esterase activity</article-title><source>FEMS Microbiol. Lett.</source><year>2005</year><volume>245</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.femsle.2005.02.018</pub-id><?supplied-pmid 15796978?><pub-id pub-id-type="pmid">15796978</pub-id></element-citation></ref><ref id="B94-antibiotics-12-01462"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahaman</surname><given-names>M.M.</given-names></name>
<name><surname>Huq</surname><given-names>I.</given-names></name>
<name><surname>Dey</surname><given-names>C.R.</given-names></name>
</person-group><article-title>Superiority of MacConkey&#x02019;s agar over salmonella-shigella agar for isolation of <italic toggle="yes">Shigella dysenteriae</italic> type 1</article-title><source>J. Infect. Dis.</source><year>1975</year><volume>131</volume><fpage>700</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1093/infdis/131.6.700</pub-id><?supplied-pmid 1094073?><pub-id pub-id-type="pmid">1094073</pub-id></element-citation></ref><ref id="B95-antibiotics-12-01462"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGwire</surname><given-names>B.S.</given-names></name>
<name><surname>Kulkarni</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Interactions of anti-microbial peptides with Leishmania and trypanosomes and their functional role in host parasitism</article-title><source>Exp. Parasitol.</source><year>2010</year><volume>126</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2010.02.006</pub-id><?supplied-pmid 20159013?><pub-id pub-id-type="pmid">20159013</pub-id></element-citation></ref><ref id="B96-antibiotics-12-01462"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebeling</surname><given-names>J.</given-names></name>
<name><surname>Knispel</surname><given-names>H.</given-names></name>
<name><surname>Hertlein</surname><given-names>G.</given-names></name>
<name><surname>F&#x000fc;nfhaus</surname><given-names>A.</given-names></name>
<name><surname>Genersch</surname><given-names>E.</given-names></name>
</person-group><article-title>Biology of Paenibacillus larvae, a deadly pathogen of honey bee larvae</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>7387</fpage><lpage>7395</lpage><pub-id pub-id-type="doi">10.1007/s00253-016-7716-0</pub-id><pub-id pub-id-type="pmid">27394713</pub-id></element-citation></ref><ref id="B97-antibiotics-12-01462"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerbod</surname><given-names>D.</given-names></name>
<name><surname>Edgcomb</surname><given-names>V.P.</given-names></name>
<name><surname>Noel</surname><given-names>C.</given-names></name>
<name><surname>Zenner</surname><given-names>L.</given-names></name>
<name><surname>Wintjens</surname><given-names>R.</given-names></name>
<name><surname>Delgado-Viscogliosi</surname><given-names>P.</given-names></name>
<name><surname>Holder</surname><given-names>M.E.</given-names></name>
<name><surname>Sogin</surname><given-names>M.L.</given-names></name>
<name><surname>Viscogliosi</surname><given-names>E.</given-names></name>
</person-group><article-title>Phylogenetic position of the trichomonad parasite of turkeys, <italic toggle="yes">Histomonas meleagridis</italic> (Smith) Tyzzer, inferred from small subunit rRNA sequence1</article-title><source>J. Eukaryot. Microbiol.</source><year>2001</year><volume>48</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1111/j.1550-7408.2001.tb00185.x</pub-id><pub-id pub-id-type="pmid">11456328</pub-id></element-citation></ref><ref id="B98-antibiotics-12-01462"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segovia</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Leishmania</italic> gene amplification: A mechanism of drug resistance</article-title><source>Ann. Trop. Med. Parasitol.</source><year>1994</year><volume>88</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1080/00034983.1994.11812849</pub-id><pub-id pub-id-type="pmid">8067807</pub-id></element-citation></ref><ref id="B99-antibiotics-12-01462"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponte-Sucre</surname><given-names>A.</given-names></name>
<name><surname>Gamarro</surname><given-names>F.</given-names></name>
<name><surname>Dujardin</surname><given-names>J.-C.</given-names></name>
<name><surname>Barrett</surname><given-names>M.P.</given-names></name>
<name><surname>L&#x000f3;pez-V&#x000e9;lez</surname><given-names>R.</given-names></name>
<name><surname>Garc&#x000ed;a-Hern&#x000e1;ndez</surname><given-names>R.</given-names></name>
<name><surname>Pountain</surname><given-names>A.W.</given-names></name>
<name><surname>Mwenechanya</surname><given-names>R.</given-names></name>
<name><surname>Papadopoulou</surname><given-names>B.</given-names></name>
</person-group><article-title>Drug resistance and treatment failure in leishmaniasis: A 21st century challenge</article-title><source>PLoS Neglected Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0006052</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006052</pub-id></element-citation></ref><ref id="B100-antibiotics-12-01462"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rochford</surname><given-names>G.</given-names></name>
<name><surname>Molphy</surname><given-names>Z.</given-names></name>
<name><surname>Kavanagh</surname><given-names>K.</given-names></name>
<name><surname>McCann</surname><given-names>M.</given-names></name>
<name><surname>Devereux</surname><given-names>M.</given-names></name>
<name><surname>Kellett</surname><given-names>A.</given-names></name>
<name><surname>Howe</surname><given-names>O.</given-names></name>
</person-group><article-title>Cu(ii) phenanthroline&#x02013;phenazine complexes dysregulate mitochondrial function and stimulate apoptosis</article-title><source>Metallomics</source><year>2020</year><volume>12</volume><fpage>65</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1039/c9mt00187e</pub-id><pub-id pub-id-type="pmid">31720645</pub-id></element-citation></ref><ref id="B101-antibiotics-12-01462"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>F.</given-names></name>
<name><surname>Perrin</surname><given-names>D.</given-names></name>
<name><surname>Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Monod</surname><given-names>J.</given-names></name>
</person-group><article-title>Operon: A group of genes with the expression coordinated by an operator</article-title><source>C. R. Hebd. Seances Acad. Sci.</source><year>1960</year><volume>250</volume><fpage>1727</fpage><lpage>1729</lpage><comment>(In French)</comment></element-citation></ref><ref id="B102-antibiotics-12-01462"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lanois-Nouri</surname><given-names>A.</given-names></name>
<name><surname>Pantel</surname><given-names>L.</given-names></name>
<name><surname>Fu</surname><given-names>J.</given-names></name>
<name><surname>Houard</surname><given-names>J.</given-names></name>
<name><surname>Ogier</surname><given-names>J.-C.</given-names></name>
<name><surname>Polikanov</surname><given-names>Y.S.</given-names></name>
<name><surname>Racine</surname><given-names>E.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Gaudriault</surname><given-names>S.</given-names></name>
<name><surname>Givaudan</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The Odilorhabdin Antibiotic Biosynthetic Cluster and Acetyltransferase Self-Resistance Locus Are Niche and Species Specific</article-title><source>mBio</source><year>2022</year><volume>13</volume><elocation-id>e0282621</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.02826-21</pub-id><pub-id pub-id-type="pmid">35012352</pub-id></element-citation></ref><ref id="B103-antibiotics-12-01462"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kazemi-Rad</surname><given-names>E.</given-names></name>
<name><surname>Mohebali</surname><given-names>M.</given-names></name>
<name><surname>Khadem-Erfan</surname><given-names>M.B.</given-names></name>
<name><surname>Saffari</surname><given-names>M.</given-names></name>
<name><surname>Raoofian</surname><given-names>R.</given-names></name>
<name><surname>Hajjaran</surname><given-names>H.</given-names></name>
<name><surname>Hadighi</surname><given-names>R.</given-names></name>
<name><surname>Khamesipour</surname><given-names>A.</given-names></name>
<name><surname>Rezaie</surname><given-names>S.</given-names></name>
<name><surname>Abedkhojasteh</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach</article-title><source>Exp. Parasitol.</source><year>2013</year><volume>135</volume><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2013.07.018</pub-id><pub-id pub-id-type="pmid">23928349</pub-id></element-citation></ref><ref id="B104-antibiotics-12-01462"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brachmann</surname><given-names>A.O.</given-names></name>
<name><surname>Forst</surname><given-names>S.</given-names></name>
<name><surname>Furgani</surname><given-names>G.M.</given-names></name>
<name><surname>Fodor</surname><given-names>A.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Xenofuranones A and B: Phenylpyruvate Dimers from <italic toggle="yes">Xenorhabdus szentirmaii</italic></article-title><source>J. Nat. Prod.</source><year>2006</year><volume>69</volume><fpage>1830</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1021/np060409n</pub-id><pub-id pub-id-type="pmid">17190473</pub-id></element-citation></ref><ref id="B105-antibiotics-12-01462"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Houard</surname><given-names>J.</given-names></name>
<name><surname>Aumelas</surname><given-names>A.</given-names></name>
<name><surname>No&#x000eb;l</surname><given-names>T.</given-names></name>
<name><surname>Pages</surname><given-names>S.</given-names></name>
<name><surname>Givaudan</surname><given-names>A.</given-names></name>
<name><surname>Fitton-Ouhabi</surname><given-names>V.</given-names></name>
<name><surname>Villain-Guillot</surname><given-names>P.</given-names></name>
<name><surname>Gualtieri</surname><given-names>M.</given-names></name>
</person-group><article-title>Cabanillasin, a new antifungal metabolite, produced by entomopathogenic <italic toggle="yes">Xenorhabdus cabanillasii</italic> JM26</article-title><source>J. Antibiot.</source><year>2013</year><volume>66</volume><fpage>617</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1038/ja.2013.58</pub-id></element-citation></ref><ref id="B106-antibiotics-12-01462"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>S.W.</given-names></name>
<name><surname>Proschak</surname><given-names>A.</given-names></name>
<name><surname>Jaskolla</surname><given-names>T.W.</given-names></name>
<name><surname>Karas</surname><given-names>M.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Structure elucidation and biosynthesis of lysine-rich cyclic peptides in <italic toggle="yes">Xenorhabdus nematophila</italic></article-title><source>Org. Biomol. Chem.</source><year>2011</year><volume>9</volume><fpage>3130</fpage><lpage>3132</lpage><pub-id pub-id-type="doi">10.1039/c1ob05097d</pub-id><?supplied-pmid 21423922?><pub-id pub-id-type="pmid">21423922</pub-id></element-citation></ref><ref id="B107-antibiotics-12-01462"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Racine</surname><given-names>E.</given-names></name>
<name><surname>Gualtieri</surname><given-names>M.</given-names></name>
</person-group><article-title>From worms to drug candidate: The story of odilorhabdins, a new class of anti-microbial agents</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>2893</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02893</pub-id><pub-id pub-id-type="pmid">31921069</pub-id></element-citation></ref><ref id="B108-antibiotics-12-01462"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xi</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Bi</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Two novel cyclic depsipeptides Xenematides F and G from the entomopathogenic bacterium <italic toggle="yes">Xenorhabdus budapestensis</italic></article-title><source>J. Antibiot.</source><year>2019</year><volume>2</volume><fpage>736</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/s41429-019-0203-y</pub-id></element-citation></ref><ref id="B109-antibiotics-12-01462"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<name><surname>Meng</surname><given-names>F.</given-names></name>
<name><surname>Qiu</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Two novel anti-microbial peptides purified from the symbiotic bacteria <italic toggle="yes">Xenorhabdus budapestensis</italic> NMC-10</article-title><source>Peptides</source><year>2012</year><volume>35</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2012.03.027</pub-id><?supplied-pmid 22497806?><pub-id pub-id-type="pmid">22497806</pub-id></element-citation></ref><ref id="B110-antibiotics-12-01462"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reimer</surname><given-names>D.</given-names></name>
<name><surname>Nollmann</surname><given-names>F.I.</given-names></name>
<name><surname>Schultz</surname><given-names>K.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Xenortide Biosynthesis by Entomopathogenic <italic toggle="yes">Xenorhabdus nematophila</italic></article-title><source>J. Nat. Prod.</source><year>2014</year><volume>77</volume><fpage>1976</fpage><lpage>1980</lpage><pub-id pub-id-type="doi">10.1021/np500390b</pub-id><pub-id pub-id-type="pmid">25080196</pub-id></element-citation></ref><ref id="B111-antibiotics-12-01462"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Rhabdopeptide/Xenortide-like peptides from <italic toggle="yes">Xenorhabdus innexi</italic> with terminal amines showing potent antiprotozoal activity</article-title><source>Org. Lett.</source><year>2018</year><volume>20</volume><fpage>5116</fpage><lpage>5120</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.8b01975</pub-id><pub-id pub-id-type="pmid">30095261</pub-id></element-citation></ref><ref id="B112-antibiotics-12-01462"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bi</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Rhabdopeptides from <italic toggle="yes">Xenorhabdus budapestensis</italic> SN84 and their nematicidal activities against <italic toggle="yes">Meloidogyne incognita</italic></article-title><source>J. Agric. Food Chem.</source><year>2018</year><volume>66</volume><fpage>3833</fpage><lpage>3839</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.8b00253</pub-id><pub-id pub-id-type="pmid">29597344</pub-id></element-citation></ref><ref id="B113-antibiotics-12-01462"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohlendorf</surname><given-names>B.</given-names></name>
<name><surname>Simon</surname><given-names>S.</given-names></name>
<name><surname>Wiese</surname><given-names>J.</given-names></name>
<name><surname>Imhoff</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Szentiamide, an N-formylated cyclic depsipeptide from <italic toggle="yes">Xenorhabdus szentirmaii</italic> DSM 16338T</article-title><source>Nat. Prod. Commun.</source><year>2011</year><volume>6</volume><fpage>1247</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1177/1934578X1100600909</pub-id><?supplied-pmid 21941889?><pub-id pub-id-type="pmid">21941889</pub-id></element-citation></ref><ref id="B114-antibiotics-12-01462"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nollmann</surname><given-names>F.I.</given-names></name>
<name><surname>Dowling</surname><given-names>A.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.</given-names></name>
<name><surname>Deckmann</surname><given-names>K.</given-names></name>
<name><surname>Gr&#x000f6;sch</surname><given-names>S.</given-names></name>
<name><surname>Ffrench-Constant</surname><given-names>R.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Synthesis of szentiamide, a depsipeptide from entomopathogenic <italic toggle="yes">Xenorhabdus szentirmaii</italic> with activity against <italic toggle="yes">Plasmodium falciparum</italic></article-title><source>Beilstein J. Org. Chem.</source><year>2012</year><volume>8</volume><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.3762/bjoc.8.60</pub-id><?supplied-pmid 22563351?><pub-id pub-id-type="pmid">22563351</pub-id></element-citation></ref><ref id="B115-antibiotics-12-01462"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monteagudo-Cascales</surname><given-names>E.</given-names></name>
<name><surname>Santero</surname><given-names>E.</given-names></name>
<name><surname>Canosa</surname><given-names>I.</given-names></name>
</person-group><article-title>The Regulatory Hierarchy Following Signal Integration by the CbrAB Two-Component System: Diversity of Responses and Functions</article-title><source>Genes</source><year>2022</year><volume>13</volume><elocation-id>375</elocation-id><pub-id pub-id-type="doi">10.3390/genes13020375</pub-id><pub-id pub-id-type="pmid">35205417</pub-id></element-citation></ref><ref id="B116-antibiotics-12-01462"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishihama</surname><given-names>A.</given-names></name>
</person-group><article-title>Modulation of the nucleoid, the transcription apparatus, and the translation machinery in bacteria for stationary phase survival</article-title><source>Genes Cells</source><year>1999</year><volume>4</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2443.1999.00247.x</pub-id><pub-id pub-id-type="pmid">10320479</pub-id></element-citation></ref><ref id="B117-antibiotics-12-01462"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vogel</surname><given-names>J.</given-names></name>
<name><surname>Luisi</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Hfq and its constellation of RNA</article-title><source>Nat. Rev. Microbiol.</source><year>2011</year><volume>9</volume><fpage>578</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2615</pub-id><pub-id pub-id-type="pmid">21760622</pub-id></element-citation></ref><ref id="B118-antibiotics-12-01462"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cech</surname><given-names>G.M.</given-names></name>
<name><surname>Szalewska-Pa&#x00142;asz</surname><given-names>A.</given-names></name>
<name><surname>Kubiak</surname><given-names>K.</given-names></name>
<name><surname>Malabirade</surname><given-names>A.</given-names></name>
<name><surname>Grange</surname><given-names>W.</given-names></name>
<name><surname>Arluison</surname><given-names>V.</given-names></name>
<name><surname>W&#x00119;grzyn</surname><given-names>G.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Escherichia coli</italic> Hfq Protein: An Unattended DNA-Transactions Regulator</article-title><source>Front. Mol. Biosci.</source><year>2016</year><volume>3</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2016.00036</pub-id><?supplied-pmid 27517037?><pub-id pub-id-type="pmid">27517037</pub-id></element-citation></ref><ref id="B119-antibiotics-12-01462"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King</surname><given-names>K.A.</given-names></name>
<name><surname>Caudill</surname><given-names>M.T.</given-names></name>
<name><surname>Caswell</surname><given-names>C.C.</given-names></name>
</person-group><article-title>A comprehensive review of small regulatory RNAs in Brucella spp</article-title><source>Front. Vet.-Sci.</source><year>2022</year><volume>9</volume><fpage>1026220</fpage><pub-id pub-id-type="doi">10.3389/fvets.2022.1026220</pub-id><pub-id pub-id-type="pmid">36532353</pub-id></element-citation></ref><ref id="B120-antibiotics-12-01462"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponath</surname><given-names>F.</given-names></name>
<name><surname>H&#x000f6;r</surname><given-names>J.</given-names></name>
<name><surname>Vogel</surname><given-names>J.</given-names></name>
</person-group><article-title>An overview of gene regulation in bacteria by small RNAs derived from mRNA 3&#x02032; ends</article-title><source>FEMS Microbiol. Rev.</source><year>2022</year><volume>46</volume><elocation-id>fuac017</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuac017</pub-id><pub-id pub-id-type="pmid">35388892</pub-id></element-citation></ref><ref id="B121-antibiotics-12-01462"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gualtieri</surname><given-names>M.</given-names></name>
<name><surname>Ogier</surname><given-names>J.-C.</given-names></name>
<name><surname>Pag&#x000e8;s</surname><given-names>S.</given-names></name>
<name><surname>Givaudan</surname><given-names>A.</given-names></name>
<name><surname>Gaudriault</surname><given-names>S.</given-names></name>
</person-group><article-title>Draft genome sequence and annotation of the entomopathogenic bacterium <italic toggle="yes">Xenorhabdus szentirmaii</italic> Strain DSM16338</article-title><source>Genome Announc.</source><year>2014</year><volume>2</volume><fpage>e00190-14</fpage><pub-id pub-id-type="doi">10.1128/genomeA.00190-14</pub-id><pub-id pub-id-type="pmid">24625876</pub-id></element-citation></ref><ref id="B122-antibiotics-12-01462"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Qiu</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Complete genome sequence data of <italic toggle="yes">Xenorhabdus budapestensis</italic> strain C72, a candidate biological control agent from China</article-title><source>Plant Dis.</source><year>2021</year><volume>105</volume><fpage>3276</fpage><lpage>3278</lpage><pub-id pub-id-type="doi">10.1094/PDIS-04-21-0701-A</pub-id><pub-id pub-id-type="pmid">33970680</pub-id></element-citation></ref><ref id="B123-antibiotics-12-01462"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Windisch</surname><given-names>M.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Oral vaccination of 1-day-old turkeys with in vitro attenuated Histomonas meleagridis protects against histomonosis and has no negative effect on performance</article-title><source>Avian Pathol.</source><year>2010</year><volume>39</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1080/03079457.2010.506906</pub-id><?supplied-pmid 20954017?><pub-id pub-id-type="pmid">20954017</pub-id></element-citation></ref><ref id="B124-antibiotics-12-01462"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Spotlight on Histomonosis (blackhead disease): A re-emerging disease in turkeys and chickens</article-title><source>Avian Pathol.</source><year>2020</year><volume>49</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1080/03079457.2019.1654087</pub-id><?supplied-pmid 31393162?><pub-id pub-id-type="pmid">31393162</pub-id></element-citation></ref><ref id="B125-antibiotics-12-01462"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatfaludi</surname><given-names>T.</given-names></name>
<name><surname>Rezaee</surname><given-names>M.S.</given-names></name>
<name><surname>Liebhart</surname><given-names>D.</given-names></name>
<name><surname>Bilic</surname><given-names>I.</given-names></name>
<name><surname>Hess</surname><given-names>M.</given-names></name>
</person-group><article-title>Experimental reproduction of histomonosis caused by Histomonas meleagridis genotype 2 in turkeys can be prevented by oral vaccination of day-old birds with a monoxenic genotype 1 vaccine candidate</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>4986</fpage><lpage>4997</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.07.001</pub-id><?supplied-pmid 35835629?><pub-id pub-id-type="pmid">35835629</pub-id></element-citation></ref><ref id="B126-antibiotics-12-01462"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fosgerau</surname><given-names>K.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.</given-names></name>
</person-group><article-title>Peptide therapeutics: Current status and future directions</article-title><source>Drug Discov. Today</source><year>2015</year><volume>20</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.10.003</pub-id><pub-id pub-id-type="pmid">25450771</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-12-01462-f001"><label>Figure 1</label><caption><p>Monoxenic culture: <italic toggle="yes">Histomonas</italic>
<italic toggle="yes">meleagridis</italic> (Turkey/Austria/2922-C6/04) cells were co-cultured with <italic toggle="yes">E. coli</italic> DH5&#x003b1; cells not-supplemented M199 tissue culture media, which contained FKS (green, or n supplemented M199 tissue culture media (blue). The cells were viable and propagated up to 72h in (<bold>a</bold>) (green) or at least 48 h in (<bold>b</bold>) (blue) at 40 &#x000b0;C in the CFCM-free cultures. In those cultures, however, which were supplemented with the sterile filtered CFCM (either of the red or the yellow) TT01 colony-color variants, the cell propagation quickly ceased, both in the supplemented M199 media (red, earlier) and in the non-supplemented (but FKS-containing) M199 media, a little later, and then, the <italic toggle="yes">Histomonas</italic> cells died (data are given in the <xref rid="app1-antibiotics-12-01462" ref-type="app">Supplementary Material</xref>).</p></caption><graphic xlink:href="antibiotics-12-01462-g001" position="float"/></fig><fig position="float" id="antibiotics-12-01462-f002"><label>Figure 2</label><caption><p>A colony of the <italic toggle="yes">hfq</italic>-del regulatory mutant (<bold>left</bold>, <bold>A</bold>), and that of the the wild-type (<bold>right</bold>, <bold>B</bold>) and of <italic toggle="yes">Xenorhabdus szentirmaii</italic> DSM16339 (EMC). The spectacular iodine crystals (the end product of the phenazine biosynthesis) are missing, indicating that the phenazine-operon encoded biosynthesis pathway is switched off in the <italic toggle="yes">hfq</italic>-deleted regulatory mutant.</p></caption><graphic xlink:href="antibiotics-12-01462-g002" position="float"/></fig><table-wrap position="float" id="antibiotics-12-01462-t001"><object-id pub-id-type="pii">antibiotics-12-01462-t001_Table 1</object-id><label>Table 1</label><caption><p>Anti-microbial activities of 5-day mid-stationary-phase cell-free conditioned culture media (CFCM) of Xenorhabdus species *.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CFCM </th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">EMA</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">EMC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMK</th></tr><tr><th rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Pre-Treatment:</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">None</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Heat</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PK</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Centricon</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">None</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Heat</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PK</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Centricon</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">None</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;3 kDa</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;3 kDa</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;3 kDa</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;3 kDa</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria-Gram +</td><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus (MRSA)</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus (MSSA)</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bacteria-Gram &#x02212;</bold>
</td><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Francisella novicida</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salmonella typhimurium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Protozoa</bold>
</td><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Leishmania amazonensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Trypanosoma cruzi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Fungi</bold>
</td><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Candida albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Toxicity</bold>
</td><td colspan="11" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">J774 macrophages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td></tr></tbody></table><table-wrap-foot><fn><p>* Notes: CFCM = 5-day mid-stationary-phase cell-free conditioned culture media of <italic toggle="yes">Xenorhabdus</italic> species; EMA = X budapestensis nov. DSM16342T; EMC = <italic toggle="yes">X. szentirmaii</italic> nov. DSM16338T; EMK = <italic toggle="yes">X. innexii</italic> nov. DSM16336T; Heat = autoclaved in standard conditions (15 min, 121 &#x000b0;C, 1 Atm) and then tested; PK = indicated CFCM was pre-incubated with proteinase K (1 mg/mL for 30 min at 37 &#x000b0;C) prior to testing for anti-microbial activity; Centricon = molecular size fractionation of indicated CFCM in centricon spin columns prior to testing anti-microbial activities; Toxicty = host toxicity, tested on determined microscopically and also determining MTT metabolism of J774-line murine macrophages (serving as checking for unspecific general cytotoxicity), exposed to the respective CM at 37 &#x000b0;C for 72 h; MS and MR: methicillin-sensitive and -resistant <italic toggle="yes">Staphylococcus aureus</italic>, respectively. Activity assays were performed on cultured cells of the respective bacterial and fungal microorganisms incubated in 25&#x02013;100 microliter of a Luria&#x02013;Bertani liquid medium overnight. Each was then plated on the appropriate medium to CFU reduction assays (concerning bacterial or fungal pathogens) or using MTT utilization for protozoa. +, anti-microbial activity with greater than 80% reduction in growth after CFCM incubation compared to untreated control cells; &#x02212;, no anti-microbial activity observed.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-12-01462-t002"><object-id pub-id-type="pii">antibiotics-12-01462-t002_Table 2</object-id><label>Table 2</label><caption><p>Effect of <italic toggle="yes">Photorhabdus</italic> CFCMs on the prokaryote partner of <italic toggle="yes">Histomonas</italic>
<italic toggle="yes">meleagidis</italic> in monoxenic culture.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">E. coli</italic> DH5 Alpha</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hours</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Yellow</td><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Yellow</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Yellow</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Red</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Red</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT01 Red</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single colonies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M199 + 15% MKS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M199 + 15% MKS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M199 + 15% MKS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unchanged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unchanged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unchanged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell layer</td></tr></tbody></table><table-wrap-foot><fn><p>100 &#x003bc;L samples were taken from <italic toggle="yes">H. meleagridis</italic>/<italic toggle="yes">Esherichia coli</italic> monoxenic culture (grown in M199 media) and plated on MacConkey agar afterward, where only the <italic toggle="yes">E. coli</italic> cells can grow, while the <italic toggle="yes">H. meleagridis</italic> cells cannot.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-12-01462-t003"><object-id pub-id-type="pii">antibiotics-12-01462-t003_Table 3</object-id><label>Table 3</label><caption><p>Anti-Gram-negative activities of CFCMs of wild-type n <italic toggle="yes">hfq</italic> (del) regulatory mutant cells of <italic toggle="yes">Xenorhabdus budapestensis</italic> DSM16342 and <italic toggle="yes">X. szentirmaii</italic> DSM 16338 (EMC).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TEST ORGANIS?</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (hfq-del)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (hfq-del)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAM-NEGATIVE TARGETS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&#x02212;</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&#x02212;</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salmonella enterica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Pasteurella multocida</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&#x02212;</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Mannheimia haemolytica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Ps. aeruginosa</italic> VB (phytopathogenic)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Actinobacillus equuli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacter cloacae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+/&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Serratia marcescens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Bordetella bronchiseptica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr></tbody></table><table-wrap-foot><fn><p>Each of the tested Gram-negative bacteria of veterinary significance was completely sensitive to one or more anti-microbial compounds in the CFCM of the wild-type <italic toggle="yes">X. budapestensis</italic> DSM16342 (EMA) strain. The majority of them (except for <italic toggle="yes">E.coli</italic>, <italic toggle="yes">Salmonella</italic>, and <italic toggle="yes">Bordetella</italic>) were resistant to the anti-microbial active compound(s) present in the CFCM of the <italic toggle="yes">hfq</italic> (del) regulatory mutant of the same species (EMA). All but <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Klebsiella</italic> were sensitive to the anti-microbial ingredient present in the CFCM of the wild-type <italic toggle="yes">X. szentirmaii</italic> DSM 16338 (EMC), but each of them was fully resistant to the anti-microbial active compound(s) present in the CFCM of the <italic toggle="yes">hfq</italic> (del) regulatory mutant. Abbreviations: &#x02212;: The test organism grew in the given CFCM, so the test organism is considered resistant to the antimicrobials in the CFCM present; +: The test organism did not succeed in the given CFCM, so the test organism is considered sensitive to the antimicrobials in the CFCM present; +/&#x02212;: the test organism seemingly but hardly grew at least in one of the replicates, so the test organism is considered as somewhat resistant to the antimicrobials in the CFCM present. These data indicate that the strong anti-Gram-negative potential of the EMA strain likely, but probably not exclusively, is under the control of the <italic toggle="yes">hfq</italic>-govern genetic regulation [<xref rid="B76-antibiotics-12-01462" ref-type="bibr">76</xref>]. The anti-Gram-positive potential of EMC is limited in comparison to the EMA. It is similarly true concerning the anti-Gram-positive antibacterial potential; see <xref rid="antibiotics-12-01462-t003" ref-type="table">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-12-01462-t004"><object-id pub-id-type="pii">antibiotics-12-01462-t004_Table 4</object-id><label>Table 4</label><caption><p>Anti-Gram-positive activities of CFCMs of wild-type n <italic toggle="yes">hfq</italic> (del) regulatory mutant cells of <italic toggle="yes">Xenorhabdus budapestensis</italic> DSM16342 and <italic toggle="yes">X. szentirmaii</italic> DSM 16338 (EMC).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TEST ORGANISMS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (<italic toggle="yes">hfq</italic>-del)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (<italic toggle="yes">hfq-del</italic>)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAM-POSITIVE </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Bacillus cereus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus pseudintermedius</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> (MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus hyicus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus suis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus agalactiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Listeria monocytogenes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Erysipelothrix rhusiopathiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Corynebacterium pseudotuberculosis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Rhodococcus equi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr></tbody></table><table-wrap-foot><fn><p>It can be seen that each of the tested (pathogenic and/or zoonic) Gram-negative bacteria was completely sensitive to one or more anti-microbial compounds in the CFCM of the wild-type <italic toggle="yes">Xenorhabdus budapestensis</italic> DSM16342 (EMA) strain. The majority of them (except for <italic toggle="yes">E.coli</italic>, <italic toggle="yes">Salmonella</italic>, and <italic toggle="yes">Bordetella</italic>) were resistant to the anti-microbial active compound(s) present in the CFCM of the <italic toggle="yes">hfq</italic> (del) regulatory mutant of the same species (EMA). All but <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Klebsiella</italic> were sensitive to the anti-microbial ingredient present in the CFCM of the wild-type <italic toggle="yes">X. szentirmaii</italic> DSM 16338 (EMC), but each of them was fully resistant to the anti-microbial active compound(s) present in the CFCM of the <italic toggle="yes">hfq</italic> (del) regulatory mutant. Abbreviations: &#x02212;: The test organism grew in the given CFCM, so the test organism is considered resistant to the antimicrobials in the CFCM present; +: The test organism did not succeed in the given CFCM, so the test organism is considered sensitive to the antimicrobials in the CFCM present; +/&#x02212;: The test organism seemingly but hardly grew at least one in one of the replicates, so the test organism is considered as somewhat resistant to the antimicrobials in the CFCM present.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-12-01462-t005"><object-id pub-id-type="pii">antibiotics-12-01462-t005_Table 5</object-id><label>Table 5</label><caption><p>Intraspecific variability within the Gram-positive <italic toggle="yes">Paenibacillus larvae</italic> to anti-microbial compounds of hfq deleted mutants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TEST ORGANISMS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMA (<italic toggle="yes">hfq</italic>-del)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (WT)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EMC (<italic toggle="yes">hfq-del</italic>)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAM-POSITIVE </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Paenibaillus larvae</italic> isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-236</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-237</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-238</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-248</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-250</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-252</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML-263</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: +: The test bacterium grows, &#x02212;: The test bacterium does not grow. Each of the tested geographical isolates of the Gram-positive (deadly pathogen for honeybee larvae) <italic toggle="yes">Paeibacillus larvae</italic> [<xref rid="B96-antibiotics-12-01462" ref-type="bibr">96</xref>] bacterium species seems to be completely sensitive to (one or more) anti-microbial compounds present in the CFCM of wild-type <italic toggle="yes">Xenorhabdus budapestensis</italic> DSM16342&#x02014;mans (EMA). Six of the nine isolates, however, also seem to be sensitive to the anti-microbial active compound(s) present in the CFCM of the <italic toggle="yes">hfq</italic> (del) regulatory mutant of the same species (EMA). About half of them (mainly those which are resistant to the antimicrobials of the <italic toggle="yes">hfq</italic> (del) regulatory EMA mutant) were also resistant to the wild-type EMC CFCM, but each of them is resistant to the antimicrobials present in the CFCM of the <italic toggle="yes">hfq</italic>/del, a regulatory mutant of EMC.</p></fn></table-wrap-foot></table-wrap></floats-group></article>